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1.1 Introduction 
More than 100 hundred years ago, Johann L. W. Thudicum described a not well 
identified aliphatic alkaloid in the brain called sphingosine
1
. The structure of this 
substance was characterized only 50 years later by Carter at al.
2 
In the last years, structural and distribution studies have highlighted the critical roles of 
sphingolipids in membranes micro domains formation, skin barrier function and 
modulate on of cellular events like apoptosis, proliferation and differentiation
3-5
. 
 These discoveries along with bioactive signal function observation, increase research 
attraction and attention on sphingolipids metabolism
6-11
. 
1.2. Sphingolipids 
Sphingolipids (SPL) are one of eight categories of the LIPID MAPS classification 
system and they are described as lipids containing a sphingoid base (1,3-dihydroxy-2-
amino alkane)
 
linked by an amido group to a fatty acid and with polar headgroup, like 
phosphate and carbohydrate
12
. SPL distribution appears ubiquitous in eukaryotic. In 
particular, SPL alkane group is usually an eighteen carbons chain; C-2 and C-3, in the 
polar headgroup, are chiral and the configuration is 2S, 3R, D-Eritro. Indeed, in 
mammal cells, sphingosine appear to be the major sphingoid base, followed by 
dihydrosphingosine, while phytosphingosine, the third major type of sphingoid bases, 
has been found mainly in plants, although it was revealed in large amount in mammal 
tissues like stomach and kidney. Sphingolipids containing cholinephosphoceramide, 
known as sphingomielyn, represent 5-10% of mammalian membrane’s phospholipids. 
SPL are produced also by some prokaryotes, plants, bacteria and fungi through different 
biosynthetic pathways 
1,12
. In fungal and plants inositol-phosphoceramide is the most 
abundant constituent of the membrane phospholipids; these observations suggest a 
relevant structural dissimilarity in the polar headgroup in different species. Conversely 
the polar headgroup of glycerophospholipids are structurally very similar between 
mammal cells and fungi
12 
(Fig.1). 
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Fig. 1: Biosynthetic pathway of sphingolipids in mammalian and fungal cells. 
1.2. Ceramide 
Several studies performed by Braun
13
, and Stoffel 
14
, independently, have demonstrated 
in 1968 that the second step of sphingolipid biosynthesis is the NADPH-dependent 
reduction of a C-3 carbonyl group leading to dihydrosphingosine
15
. In mammalian cells, 
dihydrosphingosine undergoes to an N-acylation reaction forming dihydroceramide. 
Afterwards, an alkyl chain oxidation leads to ceramide which successively 
functionalized at the polar headgroup to give sphingomielyn or different 
glycosphingolipids. Conversely, in fungi, dihydrosphingosine undergoes to oxidation 
and then to N-acylation forming phytoceramide which is further converted in inositol 
phosphophytoceramide and more structurally complex derivates. In fungi, the acyl-
chain is mainly represented by C-26 hydroxy fatty acid, whereas mammal ceramide 
deerivatives are saturated C-16/C-24 fatty acid chain
16,17
. Cells produce sphingolipids 
through two different metabolic ways: catabolic and anabolic pathways. The catabolic 
pathway involves hydrolyses of complex molecules, as sphingomielyn and 
glucosphingolipid, to obtain ceramides. The anabolic pathway (also called de novo 
biosynthesis) provides an enzymatic cascade which leads to the formation of ceramides 
starting from simple and abundant substrates like L-serine and palmitoyl-CoA
1
. 
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2. Serine palmitoyltransefarse (SPT) 
Sphingolipids biosynthesis is different between species (i.e. S. cerevisiae produces 
phosphoinositol headgroup sphingolipids only, while P. pastoris both glucosylceramide 
and phosphoinositol sphingolipids headgroup), whereas the first enzymatic step of de 
novo biosynthesis is conserved across all species producing sphingolipids
2
 (Fig.2). The 
common step of the de novo synthesis is an enzymatic condensation carried out by 
serine palmitoyltransferase (SPT), a pyridoxal-5’-phosphate (PLP) dependent enzyme. 
SPT is an enzyme belonging to alfa-oxoamine synthase (AOS) family which is a PLP 
dependent family.  
 
Fig. 2: POAS family. Reactions catalyzed by POAS family members. 
SPT catalyzes a condensation between L-serine and typically C16 acyl-CoA thioester 
(palmitoyl-CoA), to give a Claisen-like C18 condensation product: 3-
ketodihydrosphingosine (KDS). Successively KDS is rapidly reduced to 
dihydrosphingosine in presence of NADPH
1,2
. SPT plays a key role in the biosynthesis 
of sphingolipids indeed regulation of SPT catalyzed step prevents accumulation of 
sphingolipids metabolites (i.e. sphingoid base) while inhibition of later biosynthetic 
steps lead to metabolite accumulation which are death effectors in various experimental 
models and pathological conditions. Therefore, SPT condensation reactions represent 
the rate-limiting step of sphingolipids biosynthesis
1
. 
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2.1. Bacterial SPT 
The first three dimensional structure of SPT was obtained by the isolation of the 
homodimeric (and water soluble) SPT from the Gram-negative bacterium S. 
paucimobilis (spSPT)
18
. The crystal structure reveals that the holo-SPT monomer (or 
internal aldimine) consists of three domains: the N-terminal, the central catalytic 
domain and the C-terminal domain. The N-terminal domain is consist of 80 residues (an 
α-helix followed by 3 β-sheets). This domain is linked with the central domain also 
called catalytic domain. In the central domain is recognized the Lys
265
 residue 
responsible of PLP cofactor binding, while 7 β-sheet is composed by about 200 
residues. The C-terminal domain is strictly linked with N-terminal domain by binding 
interactions
19
. Three dimensional crystal of the holo-enzyme revealed a homodimeric 
structure containing a conserved Lys
265
-binding-PLP residue. However, for the correct 
positioning of the PLP cofactor, (crucial for the catalytic activity), π-stacking 
interactions between the pyridine ring and His
159
 are required. PLP interacts also with 
other residues such as Asn
138
, Asp
231
, His
234
, Thr
262
, Gly
134
 and Tyr
135
. Furthermore, an 
Arg
379 
is needed for the positioning of the L-serine in the catalytic site because of 
crucial interaction with the carboxy moiety of the substrate
1
.  
Other SPT homologues, like Sphingobacterium multivorum SPT (SmSPT) and 
Sphingobacterium wittichii (SwSPT), exhibit difference at few levels. SmSPT have a 
70% sequence identity and in active site the external aldimine (formed by the PLP and 
serine) is linked by two water molecules to two aminoacid residues, Ser
81 
and Met
271
, 
and (not to a Lys)
20
. Three-dimensional structure of SwSPT reveals a larger active site 
than in SpSPT, probably because of the use of a larger acylated-ACP thioester 
substrate
21,22
. 
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2.2. Eukaryotic SPT 
Eukaryotic SPT is a heterodimer consisting in two subunits, LCB1 and LCB2, both 
linked to endoplasmatic reticulum (ER) and they are encoded by two different genes, 
lcb1 (SPTLC1) and lcb2 (SPTLC2), composed by 15 exons of 85 kbp size localized on 
chromosome 9, arm q21-q22, and 12 exons of 110 kbp size localized on chromosome 
14, arm q24.3-q3 respectively. These genes encode for proteins of 53 and 63 kDa, with 
20 % sequence identity that is probably critical for dimerization
23,24
. LCB proteins have 
95% identity between mammals and 40% between mammals and yeast. The sequencing 
of SPTLC1 and SPTLC2 genes in Saccharamyces cerevisiae revealed that the active 
site of eukaryotic SPT is localized in the LCB2 subunit; this observation is suggested by 
detection of conserved residues of AOS’s family (one lysine, two hystidine and an 
aspartate) which are essential to lock the PLP cofactor in the active site
1,2
. LCB1 
subunit appears crucial for SPT’s catalytic activity. The lack of this subunit expression 
or a missense mutation in SPTLC1 gene causes alteration of SPT’s catalytic activity25. 
Furthermore, CHO cells line defective in SPTLC1 transcription express lower levels of 
LCB2. To obtain an overexpression of LCB2 is required an overexpression of LCB1 
and LCB2. Moreover, it appears to be unstable when it is not associated with the LCB1. 
On contrary an high level of LCB1 do not require an overexpression of LCB2. Both 
monomers have only one highly hydrophobic transmembrane domain (TMD). The 
catalytic site has a cytosolic orientation indeed indirect immunocytochemical analysis 
indicated that C-termini and N-termini of LCB1 have cytosol and lumen orientation 
respectively
26
. LCB1 and LCB2 are ER membrane integrated proteins type I. Another 
isoform of LCB2 called LCB3 is expressed only in certain tissues.  
In yeast this enzyme is constituted by the so called “SPOTS COMPLEX” that’s encodes 
for SPT–ORM1/2-Tsc3-Sac1 (phosphatase)27. Therefore, LCB1 and LCB2 subunits are 
associated with a third subunit, Tsc3, which is required for the maximal SPT activity. 
This heterodimeric structure is associated with oromucosoids proteins (ORM1/2) which 
are able to negatively regulate SPT. 
Recently for human SPT two novel small subunits named ssSPTa and ssSPTb were 
discovered. These subunits can enhance activity >10 fold when bound to LCB1-LCB2 
heterodimer. Moreover orosomucoid-like (ORMDL) proteins appear to be able to 
interact with the LCB1-LCB2 heterodimer
28
.  
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2.3. Substrate 
Palmitoyl-CoA is the more kindred acyl-CoA thioester substrate of SPT in mammalian 
cells; on the other hand pentadecanoyl-CoA and heptadecanoyl-CoA are also good 
substrates less abundant. L- and D- serine are SPT amino acid substrates. SPT is able to 
form the Schiff’s bases with both enantiomers but the alfa-deprotonation step (before 
acylation) proceeds only with  L-serine substrate. Thus L-serine is the common SPT’s 
substrate in the de novo synthesis. The hydroxyl, carboxyl and amino groups of L-serine 
appear to be necessary for interaction with SPT; neither L-alanine, L-serinamide, D,L-
serinol and nor L-serine methyl ester not in the formation of [ 
3
H]KDS from L-[ 
3
H]serine, indicating that the hydroxyl, amino, and carboxyl groups of L-serine are 
responsible for the recognition of the amino acid substrate by the SPT enzyme
29
. 
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3. Reaction mechanism 
SPT catalyzes a Claisen like condensation of L-serine and palmitoyl-CoA which leads 
to 3-KDS as final product. SPT reaction mechanism proceeds across six step: 1) 
formation of the Schiff base between L-serine and PLP, 2) L-serine α-hydrogen 
removing; 3) nucleophilic attack to palmitoyl-CoA (formation a transient acylated 
adduct), 4) decarboxylation, 5) protonation of α-carbanion and 6) KDS release (Fig.3). 
Assays conducted with purified enzyme from chinese hamster ovary cell, suggested that 
one molecule of mammalian SPT is capable of catalyzing maximally of 80 cycles of 
these steps per minute
30
. 
 
Fig. 3: Catalytic mechanism of SPT. 
The PLP cofactor catalyses all the reaction mechanism. Interaction of PLP aldehyde 
group and Lys
265
 lead to a Schiff base (internal aldimine) in the active site. 
Spectrophotometric analysis of holo SPT revealed two UV absorption peaks which 
represent two tautomers of the Schiff base PLP-Lys
265
: the enolamine (338 nm) and 
ketoenamine (426 nm). Moreover, Crystalline structure of S. Multivorum and S. 
Paucimobilis SPT highlighted that PLP has Van der Walls interaction with His
159
 and 
Ala
233
.  
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Fig. 4: Spectrophotometric analysis of holo SPT 
Addiction of L-serine to the holo-enzyme causes drastically changes in the UV spectra 
due to the formation of a new Schiff base between PLP and L-serine (external 
aldimine). Two intermediate adducts are identified: first adduct has an absorption 
similar to holo-SPT while the other one has a maximum peak at 426 nm (which 
represent the ketoenaminic tautomer of the new Schiff base) (Fig.4). The interaction of 
PLP with L-serine causes a rotation of pyridine ring or a torsion of the Schiff base C4-
C4’ bound.  
Once the external aldimine is formed, L-serine is conformationally stabilized by 
interaction of the carboxyl group with His
159
 Nε2 (hydrogen bond) and by interaction of 
the hydroxylic group with the PLP phosphate group and a molecule of water. These 
interactions fixed the PLP-L-serine complex allowing a perpendicular orientation (80°) 
of Cα-COO bond to imine-pyridine plane.  
The next step of the reaction mechanism is represented by the formation of a new C-C 
bond via a Claisen like condensation. Two different intermediate may be involved in the 
nucleophilic substitution: the decarboxylated intermediate or that one generated after 
removal of the -H. In order to understand the intermediate involved in the nucleophilic 
substitution reaction some experiments have been developed in presence of a palmitoyl-
CoA analogue S-(2-oxoheptadecyl)-CoA. This compound has a methylene group 
inserted between the sulphur atom and the carbonyl groups which doesn’t allow the 
nucleophilic substitution. Data obtained performing the enzymatic reaction in presence 
14 
 
of S-(2-oxoheptadecyl)-CoA and deuterated solvent showed the α-hydrogen switch with 
the deuterated solvent increase of about 100 times (high peak) at 426 nm. Therefore, α-
deprotonation of external aldimine is improved in presence of palmitoyl-CoA substrate 
and a significative amount of quinoid adduct have been formed. This suggests that the 
quinoid adduct attack palmitoyl-CoA thioester to form the C-C bond. A faster α-
deprotonation of external aldimine in presence of palmitoyl-CoA reduce the risk of 
intermediates accumulation which can form pyridoxamine-5’-phosphate (PMP) after 
transamination reaction (PMP can’t be converted to PLP thereby the enzyme is 
inactivated). According to Dunathan hypothesis, the -deprotonation process takes 
place when the bond involved in the nucleophilic substitution is perpendicular to the 
imine-pyridine place. The reaction takes place thanks to the complete overlap between 
the -orbital (occupied) of the designed bond and the free -orbital of the conjugate 
imine-pyridine system. The increase of -deprotonation process in presence of 
palmitoyl-CoA is related to a strictly stereochemical control of the reaction. In the 
external aldimine conformation the C-H bond is 40° rotated with respect to the imine-
pyridine plane avoiding the -deprotonation process. This conformation is generated by 
interaction of the carboxyl group of L-serine with His
159
 as depicted in the SPT-PLP-
serine crystal structure. Computational study showed that palmitoyl-CoA induced 
conformational change is related to the displacement of the hydrogen interaction of L-
serine with His
159
: palmitoyl-CoA interacts with His
159
 (hydrogen bond) whereas L-
serine performs a new interaction with the guanidine group of Arg
390 
rotating the C-N 
bond of 50°. In this new conformation the C-H bond of L-serine is perpendicular to 
the imine-pyridine plane promoting the -deprotonation. 
The nucleophilic substitution of quinoid intermediate to the acyl-CoA thioester 
carboxylic group leads to a β-keto-acid derivates. The interaction between palmitoyl-
CoA and His
159
 promotes the C-C bond formation by acidic catalysis played by His
159
: 
this residue exchange an hydrogen with the carboxylic group of palmitoyl-CoA 
inducing the right positioning. The product forms an hydrogen bond with His
159
 (the 
oxygen of the carbonyl group interact with the hydrogen of His
159). Then β-keto-acid 
derivates undergoes to decarboxylation and release of the final adduct (KDS). 
Generally PLP catalyzed reactions occur through decarboxylation process catalyzed by 
the electron withdrawing immine-pyridine system. Instead SPT decarboxylation 
reaction is promoted by the correct position of the carboxyl group by His
159
.
1 
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4. Inhibitors 
Natural inhibitors of SPT have been discovered. Sphingofungine, lipoxamicina 
(neoenactin M1), and myriocin (ISP-1/thermozymocidin) (Fig.5) are potent and highly 
selective inhibitors of both fungine and mammals SPT in cell-free models with 
nanomolar IC50. These compounds are structurally similar to the postulated transitory 
adduct formed by the L-serine and palmitoyl-CoA during the condensation suggesting 
the crucial role of a transitory adduct of these compound with PLP in the strong 
inhibition activity.  
Indeed, the inhibitory activity of sphingofungine B is highly dependent on 
stereochemistry
31,32
. 
The crucial role of sphingofungine B stereochemistry has been demonstrated: the C14 
hydroxyl group of sphingofungine B yields potent inhibitory activity but it’s not crucial 
for the activity. On the other hand, the configuration of the stereogenic centers in the α, 
β, γ and δ positions from carbonilic group are essential for the inhibitory activity32,33.  
Viridiofungins were first isolated by Harris and co-workers in 1993 from the fungus, 
Trichoderma viride.
 
This family of alkyl citrates exhibited broad spectrum of anti-
fungal properties with minimum fungicidal concentrations in the range of 1–20 μg/mL 
against a number of species. Furthermore, viridiofungins inhibited rat and yeast 
squalene synthesis. This antifungal activity is unrelated to the inhibition of ergosterol 
biosynthesis. Instead, viridiofungins showed very potent (nanomolar range) inhibitory 
activity against serine palmitoyltransferase
34
. 
 
 
Fig. 5: Structure of  natural  SPT inhibitors.  
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4.1. Penicillamine 
Penicillamine (Pen) is an α-amino acid and a characteristic degradation product of 
penicillins, used in Wilson's disease as copper chelator to form mixed disulfides with 
cystein. The enantiomer used as pharmaceutical drug is D-Pen. It has been well 
established that both enantiomers and racemic mixture exerts anti-PLP activity by 
inhibiting several PLP-dependent enzymes such as alanine aminotransferase, aspartate 
aminotransferase, glutamate decarboxylase, hystidine decarboxylase and serine 
hydroxymethyl transferase. L-Pen has the stronger inhibitory activity thanks to the 
structure similarity with the enzyme’s naturally substrate (L-amino acids) (Fig.6).  
 
 
Fig. 6: L-amino acids inhibitors of SPT. 
A recent research developed by Campopiano group, have clarified Pen inhibitory action 
and mechanism on SPT from Sphingomonas Paucimobilis (spSPT). Incubation of D-
Pen and L-Pen with spSPT results in different percentage of enzyme inhibition: 
incubation of 5 mM L-Pen with spSPT reduces enzyme activity to 3% while incubation 
with D-Pen decreases enzyme activity to 34%. Pen inhibition is reversible and the 
mechanism of SPT inactivation occurs by disabling the PLP cofactor. Indeed, 
incubation of enzyme inactivated by D-Pen and L-Pen with a buffer containing 50 µM 
of PLP, restore the SPT activity to 80% and 57 % respectively. Inability to restore 100% 
of the activity using a dialyzing buffer is due, probably, to possible additional 
competitive reactions that irreversibly modify the proteins. The Pen thiol-group plays a 
crucial role in the inhibition mechanism. The thiol-group is more nucleophilic than the 
hydroxyl group of the L-Ser and it’s able to interact with PLP aldehyde leading to 
PLP:thiazolidine (PLP:TA) adduct (Fig.7). 
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Fig. 7: Addition of L-Pen to SPT leads to formation of a PLP:TA adduct via an external aldimine intermediate (P 
represents group phosphate). 
The inhibition reaction could be monitored observing the disappearance of free PLP 
peaks at 390 nm and appearance of a new peak at 333 nm (thiazolidine adduct). Using 
the same spectrophotometric approach, a time dependent disappearance of holo SPT 
ketoenamine (420 nm) and appearance of a thiazolidine adduct have been observed after 
addiction of L-Pen to holo-SPT. ESI-MS analysis of these samples confirmed the 
formation of a PLP:TA adduct. Moreover L-Pen and L-cystein activities have been 
compared highlighting a faster inhibitory activity of L-Pen that could be related to the 
presence of gem-dimethyl group enhancing cycle formation through a Thorpe-Ingold 
effect
35
(Fig.35). 
 
Fig. 8: (A) UV-visible spectrum of 20 mM holo-SPT (solid line) shows typical peaks at 335 nm and 420 nm due to 
enolimine and ketoenamine forms of the PLP cofactor respectively. Addition of 10mM L-Cys to holo- SPT (broken 
lines) led to formation of a thiazolidine adduct (333 nm peak) over a 30 minute period, with concomitant loss of the 
420 nm peak (B) improved thiazolidine formation in SPT over 30 minutes by addition of 10 mM L-Pen. 
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4.2. Cycloserine 
 
β-chloro-L-alanine and L-cycloserine has been used as SPT inhibitors. These 
compounds are potent inhibitors of several PLP-dependent enzymes, therefore their use 
as specific inhibitors is limited
36,37
. 
Cycloserine (Fig.9a) is cyclic α-aminoacid well known to inhibit many PLP-dependent 
enzymes (transaminase, racemase and decarboxylase)
38-40
. It exists as two enantiomers: 
D-cycloserine (DCS) and L-cycloserine (LCS).  
 
 
 
 
Fig. 9a: “Conformations” and “ structures” of  D- and L- α-amino acids inhibitors of SPT. 
 
The mechanism of antibacterial activity is based on the inhibition of alanine racemase, a 
PLP-dependent enzyme that synthesize D-alanine for the formation of D-alanyl-D-
alanine dipeptide (an essential component of the peptidoglycane layer of the M. 
tuberculosis)
41
. Furthermore, DCS is an agonist of N-methyl-D-aspartic acid (NMDA) 
receptors that is implicated in several CNS pathologies and it’s used in neurological 
models of these pathologies
42
; LCS has been prepared synthetically and used as a 
modulator of lipids metabolism in biological research, indeed it is a potent inhibitor of 
SPT activity. Furthermore, it has been demonstrate that LCS inhibits mouse brain SPT 
activity in vivo after intraperitoneal injection
43
. Some authors propose a cycloserine 
inhibition mechanism based on aromatization of the PLP:cycloserine external aldimine 
(“aromatization mechanism”) by α-deprotonation that give rise to a 3-
hydroxyisoxazole–PMP adduct: the cycloserine ring remains intact and covalenty linked 
to the PLP. 
19 
 
A first study developed by Ikushiro
44
 revealed a change in SPT absorption 10 minutes 
later the addiction of LCS: the peak corresponding to the ketoenamine tautomer of the 
internal aldimine (426 nm) decreased whereas a new peak at 380 nm increased. On the 
basis of this data a mechanism of action was hypothesized: in a first attend LCS reacts 
with PLP forming and external aldimine that undergoes to decyclization of the 
isoxazolidone ring (forming a transient oxime intermediate with absorption at 380 nm) 
leading to pyridoxamine 5’-phosphate (PMP) and β-aminooxypyruvate (Fig.9b). 
 
 
Fig. 9b: Proposed mechanism of LCS inactivation of SPT by Ikushiro et al. 
 
 
In 2010 the research group of Campopiano
45
 have highlighted the enantiospecific 
inhibition of LCS and DCS and they have identified a novel decarboxylative ring-
opening mechanism for inactivation of SPT. In particular the data show that in order to 
obtain the same inhibition of SPT activity (to the same extent and over the same time) 
15-fold higher concentration of DCS is needed in comparison with LCS showing a clear 
enantiospecific difference of the enzyme active site (Fig.10). 
 
 
Fig 10: Secondary plot of 1/kapp versus 1/[inhibitor] for LCS and DCS. 
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SPT activity (monitored by continuous DTNB assay) is reduced to 1% and 22 % after 2 
hours incubation with 5 mM of DCS and LCS respectively. Furthermore incubation of 
treated samples in a buffer containing 25 M of PLP caused the recovery of SPT 
activity (83 % and 79 % of DCS and LCS inactivated samples respectively). Incubation 
of the inhibited enzyme in buffer (without PLP) doesn’t cause any further change of 
activity (the enzyme is still inactivated). These data confirm the disabling of PLP 
activity and the absence of further covalent modifications occur. The incubation of 
enzyme with DCS and LCS showed different UV-spectra. After 30 minutes from the 
addiction of 5 mM LCS new peaks appear at 330 and 380 nm and no more changes 
were observed when the incubation time was about 8 hours. Incubation of DCS with 
SPT causes the loss of the 425 nm peak and the appearance of a new peak at 380 nm. 
This peak shifted to 365 nm over time and at the same time a broad shoulder at 330 nm 
appeared (Fig.11A). These results suggest the formation of different species and the 
displace of the new PLP-Lys
265 
bond. In contrast, the UV-VISis spectra of free PLP in 
the presence of both enantiomers show the same peak at 360 nm (Fig.11B).  
 
 
Fig. 11: (A) SPT and 5 mM of LCS at time 0 (solid line), 30 seconds (long dash), 1 minute (dotted line) and 30 
minutes (dash dot). (B) SPT and 5 mM of DCS at time 0 (solid line), 30 seconds (long dash), 2 hours (dotted line) and 
10 hours (dash dot). 
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This last one result suggests that enzyme not only accommodate the PLP-cycloserine 
aldimine adduct but it’s also implicated in the formation of new different species.  
The reaction intermediates have been identified by LC ESI-MS analyses of SPT 
samples incubated with LCS: a peak at 2.8 minutes (m/z = 248) corresponding to PMP 
and another peak at 3.1 minutes (m/z = 256) corresponding to [M + H] ion of a 
hydrazine adduct formed by the derivatisation of the β-aminooxyacetaldehyde with 2,4-
dinitrophenylhydrazine (2,4-DNP) have been identified. These peak wasn’t observed in 
control experiments with free PLP and 2,4 DNP derivative. These results suggest that 
the mechanism of LCS inhibition is based on the ring-opening of LCS by cleavage of 
the amide bond: this phenomenon take place because the C-α proton in the PLP:LCS 
external aldimine cannot be in the optimal orientation to be removed by the lysine. 
Successively two different decarboxilative pathways can take place: a) the ring-opened 
intermediate is acylated (enzyme mediated mechanism) and hydrolysed to form the 
carboxylated PLP intermediate (path [a] Fig.12); b) ring-opened adduct could proceeds 
through acid catalysis with water nucleophilic attack on the CS ring (path [b] Fig. 12).  
 
Fig. 12: Novel ring-opening, decarboxylative mechanism for inactivation of SPT by LCS. Path (a) denotes an 
enzymatic, nucleophile (Nu)- mediated mechanism with an acylated intermediate. Path (b) is the direct hydrolytic 
mechanism. 
 
 
These pathways may come to form an oxime intermediate (observed as a 380 nm peak 
in the UV-visible spectrum) or decarboxylated adduct that is followed by the 
hydrolyzed immine form which conduct to PMP and β-aminooxyacetaldehyde . 
Using a SPT R378N (a mutant which contain in the active site an alterated Arg
378
 
residue that form a salt bridge with the carboxylate of the external aldimine) permit to 
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isolated intermediate and 40 fold reduced rate when compared with the wild-type 
enzyme, it was observed transient formation of a quinonoid species (formed by 
decarboxylation) at 510 nm during DCS inactivation, while inactivation with LCS 
(much faster inactivator in comparison with DCS) show a similar spectrum to the wild-
type enzyme at 380 nm
45
.  
In addition these researches has been conducted with modeling to isolated the PMP 
adduct (Fig.13). 
 
 
 
Fig.13: Left:  Fo-Fc electron density for the PMP molecule. This was calculated from molecular replacement model 
which was refined and had omitted the co-factor. The map is contoured in green at 3s (0.2 Å3). Also shown are the 
side chains of Lys265, His159, Asp231 and His234. Monomer A is shown in ribbon in cyan and monomer B in 
magenta. The additional Fo   Fc electron density ‘‘blob’’ is shown in blue, contoured at 2.7s (0.2 Å 3). A molecule of 
the β-aminooxyacetalaldehyde identified by mass spectrometry is placed in the density. Carbons are colored yellow, 
nitrogen blue, oxygen red and phosphorous orange. Right: Overlay of SPT:L-ser (2bwj) and the LCS inactivated 
form. The loop containing R378 adopts the ‘‘swung-out’’ conformation in the LCS form, in contrast to the ‘‘swung 
in’’ conformation in SPT:L-ser. The color scheme for the LCS inhibited form is as (left). For the SPT:L-ser structure, 
monomer A is colored light blue. Carbons are colored green, and other atoms are colored the same as in (left). The 
main chain of R378 adopts a very different conformation from the SPT:L-ser structure because the salt contact with 
L-ser is missing. A well-ordered molecule (red sphere) in the LCS structure is found in the same location as the L-ser 
carboxylate. The side chain of L-ser points towards the unfitted blob at the active site. 
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4.3. Myriocin 
Natural products and their derivatives are known to be excellent tools for biochemicals 
and pharmacologicals studies. Myriocin [(2S, 3R, 4R, 6E)-2-amino-3,4-dihydroxy-2-
(hydroxymethyl)-14oxo-6-eicosenoic acid]  (Fig.14a) also known as thermozymocidin 
and ISP-1, has potent immunosuppressant properties in addition to antibacterial and 
antifungal activity. 
 
Fig. 14a: myriocin structure 
Firstly isolated by thermophilic moulds Myriococcum albomyces and Mycelia sterilia, 
myriocin remains the most valuable and widely used chemical probes in sphingolipids 
research as demonstrated by several studies: the identification of the two SPT subunits 
(SPTLCB1 and SPTLCB2) by Screiber et al.
27
 and of multi-protein membrane-bound 
SPT complex (SPOTs complex) by Breslow at al.
28
 has been performed using myriocin.  
Kawasaki and collagues determined an IC50 value of 15 nM using cytotoxic T-cell line 
(CTLL-2)
46
. Moreover, a recent study has demonstrated that myriocin reduces ceramide 
levels in rd10 mouse model of retinitis pigmentosa (RP) and therefore can rescue 
photorecepetors death
47
. Despite its use, the molecular basis of myriocin inhibition of 
SPT is largely unknown. Campopiano and coworkers have recently shed light in 
molecular mechanism of SPT inhibition by myriocin using a soluble and recombinant 
form of the enzyme from Sphingomonas paucimobilis (spSPT). Uv-vis analyses after 
addition of five-fold molar excess of myriocin to holo-SPT revealed that the two 
characteristic peak at 333 nm and 420 nm (corresponding to the ketoenamine and 
enolimine forms of the external aldimine) led to an increase absorbance with maximum 
at 430 nm and the disappereance of the peak at 333 nm. This data reflects a 
transamination reaction between PLP and myriocin that lead to the formation of a stable 
an external aldimine mimicking the β-keto acid intermediate, Fig.14b and confirmed by 
LC ESI-MS analyses Fig.14.b-B. 
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Fig. 14b: SPT inhibition occurs via formation of a PLP-myriocin aldimine. (A) UV-Vis spectrum of 40 μM SPT 
before (solid line) and after 200 μM myriocin addition (dotted line). (B) The proposed structure of the inhibitory 
complex - a PLP-myriocin aldimine, 11. (C) Detection of the PLP-myriocin aldimine by LC-MS. Top, Extracted Ion 
Chromatogram at m/z 631. Bottom, high resolution mass spectrum of the PLPmyriocin aldimine, obtained by 
summing the spectra between t = 8-12 minutes. ([M+H]+, C29H48N2O11P; predicted m/z 631.29902; observed error 
4.0 ppm). * denotes a contaminant. 
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Interstingly PLP-myriocin aldimine (11) is relatively stable at 25°C. However, after 16 
hours of incubation a decrease of 430 nm peak and increase of 331 nm and 400 nm 
peaks is revelead (Fig.15). 
 
 
 
Fig.15: UV-vis analysis of the degradation of the PLP-myriocin external aldimine in wild-type SPT. The PLP-
myriocin external aldimine (solid line) is stable for 90 minutes, before a decrease at 430 nm is observed, which is 
accompanied by a concomitant increase at 331 and 400 nm over 16 hours (dotted and dashed lines). 
 
SPT:PLP-myriocin complex has a noncovalent, reversible nature and very slow off rate 
(koff) when incubated with myriocin for 10 minutes: sample dialysis in 25 µM PLP 
containg buffer for 24 hours restored enzyme activity of 60% (accompanied with UV-
Vis spectrum back to the internal aldimine). On the other hand a covalent and 
irreversible nature of myriocin-enzyme interaction has been observed when samples 
were incubated for 16 hours (Fig.16). Moreover, experiments demonstrate that myriocin 
is a competitive inhibitor for both L-serine and palmitoyl-CoA and a Ki of 967±98 nM. 
 
 
Fig.16: Relative enzymatic activity after removal of inhibiting species by dialysis. SPT was inhibited with 200 μM 
myriocin and incubated for 10 minutes (white bars) or 16 hours (grey bars) at 25 °C before removal of myriocin by 
extensive dialysis. The enzymatic activity was then determined at 0 hours, 3 hours, and 24 hours after dialysis. 
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To better understand the role of the Lys 265 in the dual reaction mechanism of 
myriocin, an incubation with five-fold molar excess of myriocin and catalytically-
inactive SPT (K265A SPT) which present active site without Lys residue was 
performed. After 16 hours the UV-Vis spectra remained unchanged in contrast with 
wild-type SPT suggesting that the initial SPT:PLP-myriocin inhibitor complex breaks 
down to form a second species that also inhibits wild-type SPT (Fig.17). 
 
 
 
Fig. 17: UV-vis analysis of SPT K265A (40 μM) showed two absorbance maxima at 326 and 402 nm (solid line). 
Upon addition of 200 μM myriocin, an immediate shift to a single peak at 425 nm occurred (dotted line), indicating 
the formation of a PLP-myriocin aldimine complex. Over 16 hours this spectrum remains unchanged (dashed line), 
indicating that the PLP-myriocin aldimine complex is not degraded by this mutant enzyme. 
 
A retro-aldol like mechanism of SPT:PLP:myriocin complex which selectively and 
covalently modifies the Lys
265
 (crucial for the enzyme-catalysed reaction) leading to 
irreversible inactivation of the enzyme was hypothesized (Fig.18). 
Mass spectrometry analyses showed a covalent adduct (14 in Fig.18) of SPT displaying 
a mass of 47.509 Da susceptible to NaBH4 of the covalent SPT-octadecenal imine 
adduct and ketone group. Peptide mass fingerprinting identified Lys
265
 as the site of 
modification. Trypsin digest and mass spectrometry analysis identify three peptide 
species which displayed monoisotopic masses consistent with Lys
265
 modified by Δ 
mass +282.24 (Fig.19). 
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Fig. 18:  Myriocin reacts with PLP in the active site to form the inhibitory PLP-myriocin aldimine 11, this species is 
stable for greater than an hour at physiological temperature with inhibition being reversible upon addition of excess 
PLP.   
 
 
 
 
Fig. 19: PLP-myriocin aldimine 11 (Fig.18) decomposes over 16 hours, at physiological temperature, to produce a 
long chain aldehyde 12 (Fig.18) that react with the active site lysine to form an imine, thus rendering the enzyme 
inactive. This covalent modification can be classed as suicide inhibition. 
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Due to the timescale of crystallization, the PLP-myricin aldimine degrades into the 
wilde-type enzyme and catalytically inactive K265A has been used to capture external 
aldimine which results stable and decompose only after seven days with a 
decarboxylation reaction. This slowness relative to wild-type complex is due to the not 
optimal orientation (“Dunathan conformation”) suggesting the crucial role of the Lys265 
in the decarboxylation of the SPT:PLP-myriocin complex (Fig.20). 
 
 
Fig. 20: Decarboxylation mechanism to account for PLP-decarboxymyriocin external aldimine observed in the 
crystal structure of SPT K265A. 
 
The crystal structure obtained highlights that the conserved residues His
159
, Asp
231
 and 
His
234
 are all in the same relative positions within the active site. Moreover, the CH2OH 
head group of myriocin interacts with the 5′-phosphate of PLP. The 3,4-cis-diol of 
decarboxymyriocin makes hydrogen bonds to the protein, notably the 3-hydroxy group 
of myriocin with the important catalytic residue His
159
; this interaction would be 
expected to be preserved in the wild type SPT:myriocin complex. The hydrogen bond 
network that surrounds and includes the 4-hydroxy group of decarboxymyriocin may be 
changed by the presence of Lys
265
 but at least some of the same network seems certain 
to persist and this too involves the same residues that interact with the carboxylate of 
the PLP-L-serine external aldimine. These interactions rationalize the competitive 
inhibition with L-serine. Accompanying these interactions are movements of the side 
chains of Tyr
73
, Arg
378
 and Arg
390
 as well as a displacement of a key conserved stretch 
of amino acids (RPPATP) that constitute a mobile loop that undergoes conformational 
changes during the catalytic cycle. The 6,7 trans double bond geometry of myriocin is 
clearly defined and we can see electron density for the carbon chain up to C9 which sits 
in the hydrophobic cleft adjacent to PLP. The carbon tail of myriocin binds in a similar 
orientation to the decanoyl-tail of the PLP-product external aldimine observed bound in 
the crystal structure of the related AOS enzyme CqsA from Vibrio cholera  consistent 
with hypothesis that myriocin mimics the condensation intermediate (Fig. 21). 
29 
 
 
 
Fig. 21: The structure of SPT K265A PLP-decarboxymyriocin aldimine inhibitory complex. (A) The biological SPT 
dimer of the decarboxylated myriocin complex. The protein is shown as a cartoon with one subunit colored pale 
green and the other pale blue. The PLP external aldimine of the decarboxylated myriocin (15) is shown in space fill 
with carbons colored yellow, nitrogen blue, phosphorous orange. The N terminii are marked as dark blue spheres 
and C-terminii as red spheres. (B) Left, The Fo-Fc map (blue chicken wire contoured at 1.8σ, carve radius 1.5A) 
calculated from a model which had never contained either PLP or myriocin. Atoms are colored as figure 6A. Right, 
the final Fo-Fc map contoured at 0.85σ with a carve radius 1.8 Å. (C) Detailed representation of the active site 
interactions, carbon atoms are colored yellow and shown in sticks for the PLP-decarboxymyriocin aldimine 15. 
Carbon atoms in protein side chains are shown as white sticks, others atoms are colored as figure 6A. The 
hydrocarbon chain of the myriocin inserts into a hydrophobic pocket. (D) Superposition of the PLP-
decarboxymyriocin external aldimine (colored as before) with the PLP-L-serine external aldimine 2W8J (cartoon 
pale orange, protein side chain carbons dark grey, aldimine carbons colored green, other atoms are colored as 
before). The key catalytic Lys265 residue is mutated to Ala in the decarboxylated myriocin complex. 
 
This structure rationalizes the retro-aldol degradation of the PLP-myriocin external 
aldimine  11 into corresponding to the C18 aldehyde 12. This mechanism requires a 
base to abstract the proton from the 3-hydroxy group of myriocin but Lys
265
 would be in 
wrong face to perform this role. However, the absolutely conserved His
159
 is positioned 
2.6 A away from the 3-hydroxy of myriocin and probably initiates the cleavage of the 
C2-C3 bond with the electrons sinking into the PLP ring. In the other hand deprotonated 
Lys
265
 is positioned to attack the newly formed C18 aldehyde species 12 to form a 
covalent aldimine adduct 14 and modifies the key catalytic lysine residue irreversibly 
and block access to the active site preventing regeneration by PLP on a biologically-
relevant timescale
46
. 
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5. Retinitis Pigmentosa 
Retinitis pigmentosa (RP) is a general term related to a wide range of rod and cone 
dystrophies characterized by progressive night blindness, visual field constriction and 
loss of acuity leading to an altered electroretinogram (ERG)
48
. Currently, there is no 
therapy able to stop the disease’s evolution based more frequently on mutations of 
genes involved in rod photoreceptors function and metabolism. Rods and cone 
photoreceptors cells death occurs through both apoptotic and non-apoptotic 
mechanisms
49
. 
In many neurodegenerative and inflammatory diseases, an increase of the intracellular 
levels of ceramide, a well-characterized death effector, has been revealed. A direct 
genetic link between retinal degeneration and sphingolipid mediated apoptosis has been 
highlighted by the discovery of a mutation in CERKL (a gene expressing ceramide 
kinase-like protein) which causes loss of function and autosomal recessive RP
50
. 
Ceramide levels are increased by de-novo biosynthesis or by activated intracellular 
sphingomyielinase which hydrolyze complex sphingolipids leading to ceramide. The 
Drosophilla model of RP (knock out of the gene encoding for one subunit of SPT) is 
characterized by a decrease of ceramide intracellular levels and protective effects in 
retinal function and morphology. Also the injection of ceramidase, a ceramide 
hydrolyzing enzyme, results in a decrease of ceramide intracellular levels and protective 
effects
51
. In the murine 661W photoreceptor cell line, oxidative stress can increase 
ceramide levels leading to cell death via mitochondrial apoptotic pathway activation and 
caspase cascade
52
. Therefore, inhibition of ceramide biosynthesis, accordingly with 
biochemical analyses, may represent a therapeutic approach for the treatment of this 
disease in humans. 
A useful model for human RP is represented by rd10 mice line
53
 which presents a 
missense mutation of the beta subunit of the rod-specific phosphodiesterase gene, and 
mimics a form of human autosomal RP. Rd10 mice retinal ceramide levels increased at 
the third week of life, which correspond to the maximum photoreceptor death period as 
well as the human RP. These high levels are constant for the following period, whereas 
in wild-type mice ceramide levels decrease during the same period reaching a plateau 
after full retinal maturity. Rod death starts about at 12 days of life (P12) and reach the 
maximum peaks at 24 days of life (P24). Indeed ERG (electroretinogram) generated by 
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rods can be recorded up to 25 days of life (P25) until 45 days of life (P45) due to death 
of the retinal cones. Rod degeneration presents the characteristic features of apoptosis
54
. 
In rd10 mice model of RP, single intraocular injections of 0.5 nmol (1 μL of 3.77 mM 
solution in DMSO) of myriocin, significantly decrease ceramide levels (17.5%) than in 
control, and rescued photoreceptors from apoptotic death whereas the ceramide levels in 
wild type are not significantly reduced (determined with the diacylglycerol kinase test).  
Eye drops consisting in a suspension of solid lipid nanoparticles (SLNs) loaded with 
myriocin, carried the drug across ocular tissues permitting trans-ocular drug 
administration: the non-invasive and long term treatment of these drops ameliorate the 
reduction of function loss and of ceramide levels (40.6%). Histological analyses (Fig. 
22) demonstrate that myriocin treated rd10 mice presents normal retinal morphologies 
and excellent maintenance of ganglion cell morphology and structure: prolonged 
treatment (over 20 days) with solid lipid nanoparticles increase photoreceptor survival, 
preserving photoreceptor morphology (rhodopsin and cone immunoreactivity in well-
organized outer segments of rods and cones and presence of well-organized dendrites in 
rod bipolar cells) and extends the ability of the retina to respond to light (demonstrated 
by the ERG)
55
. These data highlight that SPT inhibitors could be an useful tool for the 
treatment of RP.  
 
 
 
Fig. 22: Effects of myriocin-SLNs on retinal morphology. (A and B) Vertical retinal sections from rd10 mice treated 
with control SLNs (A) andmyriocin-SLNs (B) for 10 d (from P14 to P24). The outer nuclear layer (ONL) of the 
myriocin-treated retina is thicker because it contains more photoreceptor rows than the control retina. These 
micrographs are from the same animals whose ERG data are shown in Fig. 4B. INL, inner nuclear layer; OPL, outer 
plexiform layer. (C) Quantification of photoreceptor rows at P24 and P30 in rd10 mice treated with control SLNs or 
myriocin-SLNs. Data are mean and SE. *P = 0.002, **P = 0.003, t test. 
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6. Alzheimer 
Alzheimer's disease (AD) is the most common form of dementia. It was firstly 
described in 1906 by the german neuropathologist Alois Alzheimer. AD is characterized 
by short-term memory impairment, language disturbance (aphasia), confusion, 
irritability and loss of both judgment and reasoning ability, including deficiency of 
acetylcholine. The anatomical consequence of the cholinergic deficit is the atrophy and 
degeneration of subcortical cholinergic neurons (especially in the basal forebrain). This 
brain region provide cholinergic innervation to the cerebral cortex involving multiple 
neurotransmitter systems, including serotonin, glutamate, and neuropeptides. Not only 
cholinergic neurons are involved in AD, cortical and hippocampal targets are also 
interested. In the early stages (clinically silent stages) neurons degeneration  and plaques 
formation in the hippocampal cortex take place and in late stages limbic and neocortical 
sites (conclamated AD) are involved. 
Microscopic analyses of the affected parts of the brain have demonstrated the presence 
of a large amount of intracellular neurofibrillary tangles (NFT) consisting in 
microtubule-associated protein tau in the hyperphosphorilated and insoluble form. 
Moreover there are extracellular amyloid in the form of senile plaques (SP) consisting 
of a core of amyloid β-peptides (Aβ). For that reason AD represent one of the 20 
clinically defined amyloidosis disease. The severity of impairment is roughly 
proportional to tangles and plaques abundance. The observed deposited fibrils were in a 
misfolded form β-sheet called β-amyloid. These components appear elevated in the 
hippocampus and in the associative regions of the cortex. Indeed, neural injury is most 
severe in the hippocampus and neocortex. Astroglia and hippocampal neurons exposed 
to β-amyloid show characteristic changes of apoptosis. The loss of neurons is not 
uniform but it varies dramatically in relation to functional regions. Mutations in the 
genes encoding for the amyloid precursor protein (APP), a type 1 cell surface 
glycoprotein which has neurotrophic and neuroprotective activity, and proteins known 
as the presenilins (PS1 and PS2), which may be involved with secretases (α, β and γ) 
enzyme in APP processing, lead to the formation of the Aβ. The presenilins and their 
mutated forms (in the PS1 gene on chromosome 14 and in the PS2 gene on chromosome 
1) participate in APP processing leading to production, among others, of 4-kDa β-
amyloid peptide of varied amino acid lengths, predominantly 40-42 (called Aβ40 and 
Aβ42 respectively). The production of Aβ from APP appears to result from alterated 
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proteolytic cleavage of APP by the β-site APP-cleaving enzyme 1 (BACE 1)56-60. 
Apolipoprotein E (apo E) has been identified as the first of what are likely to be many 
genetic risk factors for AD, involved in transport of cholesterol and lipids in blood. The 
mechanism by which the apo E 4 protein increases the risk of AD is unknown, but a 
secondary function of the protein in β-amyloid aggregation or processing of APP has 
been suggested. Lipid metabolism and  high fat diet  are risk factors for AD. Indeed, 
adequate intracellular ceramide is required for dendritic differentiation and survival of 
Purkinje cells
61,62 
while exogenous ceramides induce neurons and astroglia death in 
culture
63-66
. Elevated ceramide levels are show to be a risk factor for AD
67-71
. 
Significant increase of the death-effector ceramide has been observed in AD patients 
neurons exposed to Aβ compared with control suggesting a molecular interaction 
between these two species. Aβ accumulation may cause oxidative stress as 
demonstrated by increased levels of the lipid peroxidation product 4-hydroxynonenal 
(4-HNE) in neurons exposed to Aβ72-74 and  alteration of  membrane lipid metabolism 
increas ceramide and sphingomielyn levels; this phenomen lead to synaptic function 
alteration, degeneration and neurons death (Fig.23). Moreover, alteration of the 
ceramide and cholesterol metabolism increases the γ-secretase’s cleavage of APP and 
enhances the production of Aβ42
75
.
  
 
 
Fig.23: Pathways of metabolism of sphingomyelin, ceramide and cholesterol, their modulation by oxidative stress, 
and their possible roles in neuronal death in AD. The production of sphingomyelin from serine and palmitoyl CoA is 
catalyzed by the enzyme serine palmitoyltransferase (SPT). Ceramides are synthesized as precursors to 
sphingomyelin and are also generated by the hydrolysis of sphingomyelin by sphingomyelinases (SMase). Exposure 
of cells to reactive oxygen species and Aβ induces ceramide production. CAPK, ceramide-activated protein kinase; 
CAPP, ceramide-activated protein phosphatase 
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. 
In pathological conditions, ceramide facilitate the mislocation of BACE 1 and γ-
secretase from outside to the lipid rafts, where secretase cleavage of APP leading to the 
Aβ. Membrane ceramide stabilize BACE 1 affecting the activity of the γ-secretase76-80. 
Moreover, SPT appear increase and positively correlates with Aβ in human autopsy 
brain cortices, directly regulates their concentration in the serum and brain. Utilizing 
wild-type hybrid mice (C57/Bl6 x C3H), during a high-fat-diet of 5 months (starting at 
4 months age) it was show an increase of SPT levels whereas in the same model a high-
fat-diet of 3 months has not showed the same increase suggesting that the duration of 
high-fat diet consumption could have effect on metabolic processes
81
.  
Also in these studies L-cycloserine (LCS) has demonstrated in vitro and in vivo 
reduction of cerebroside levels which largely consist in ceramide with polar head and 
single glucidic residue
82
. Furthermore, cognitive enhancement has been observed in AD 
patients in a duble-blind controlled trial with treatment of cycloserine (100 mg/day for 
14 days)83. In an early-onset transgenic mice model, TgCRND8, encoding a double 
mutant form of APP 695 (KM670/671NL1V717F) under the control of the PrP gene 
promoter
84, LCS has demonstrated to reduce Aβ42 ceramide levels in comparison with 
mice fed a high fat diet and also in comparison with mice fed a control chow diet. LCS 
administration cause a decrease of cortical SPT protein levels with a significant positive 
correlation with ceramide and Aβ42 levels in all the study groups. Furthermore, SPT 
appear to surround the SP in TgCRND8 mice and humans supporting the involvement 
of the enzyme in the Aβ formation. Moreover, LCS cause a decrease of the 
hyperphosphorilated tau protein reducing levels GSK3b (a kinase that mediates 
phosphorylation of tau). The administration of large doses (100 mg/kg) of LCS reduce 
immediately brain SPT levels with weight loss while low dose (25 mg/kg) show side 
effects without weight loss. Chronic LCS (by an intraperitoneal surgically implanted 
osmotic pump) administration doesn’t change brain histology, morphology, 
myelination, or memory in healthy mice with the LDH serum levels unchanged
85
. 
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7. Hereditary Sensory Neuropathy Type 1 (HSAN 1) 
HSAN 1 is a neuropathy characterized by loss of pain, temperature sensation in hands 
and feet accompanied with skin ulcers, infections and high pain
86
. In addition, 
degeneration of motor neuron occurs with consequent atrophy and weakness of distal 
muscles of hands and legs
87,88
. Today it has been identified missense mutation at the 
SPTLC1 gene encoding the first subunits of SPT
89-91
. Analysing 24 HSAN1 families 
patients, four missense mutations have been reported corresponding to C133W, C133Y, 
V144D, and G387A but recently have been reported two others mutations associated 
with HSAN 1. The most frequent mutation  observed is an C133W, while G387A is a 
relatively not common mutation and doesn’t look like disease-causing mutation92. 
Heterozygous SPTLC1 and SPTLC2 knock-out mice doesn’t develop the neuropathy. 
This data changed the common think that HSAN 1 is due to a loss of SPT function and 
haploinsufficiency should be reflected in reduced total sphingolipid levels. Indeed, the 
total sphingolipids levels are not increased in SPTLC133W transgenic mice that 
develop an age-dependent peripheral neuropathy with motor and sensory impairments
93
. 
Cells can also generate ceramide by the degradation of sphingomyelin from external 
sources and therefore they are principally able to compensate reduced de novo ceramide 
synthesis
94
. To analyze total sphingolipids levels and the correlation with de novo 
synthesis of ceramide, it has been utilized the SPT inhibitor myriocin and the ceramide 
synthase (CerS) inhibitor fumosin B1 (FB1) which lead to accumulation of 
sphingolipids (permitting to observe the type of sphingolipids accumulated). In the 
HEK133W and HEK133Y expressing the SPTLC 1 mutant line cell, result in 50% 
reduction of the sphingolipids levels utilizing FB-1 in comparison to wild-type cell not 
expressing the SPTLC1 mutant. Furthermore, presence of unusually peak in cell lines 
expressing the mutant SPTLC1 but not in the wild-type line cells have been revealed. 
This peak disappears of cell lines treatment with myriocin suggesting direct correlation 
between SPT and the peak revealed in mutant cell lines. When extracted and analyzed 
the peak revealed two different metabolites with mass to charge ratio (m/z) of 462.3 and 
448.3, these correspond to 16 and 30 Da smaller than sphiganine (SA); m/z=478.3) with 
loss mass of oxygen (16 Da) or hydroxymethyl group (30 Da), respectively. Several 
analyses reveal that these metabolites have a sphingoid backbone with lack of the 
hydroxyl group at the C1 therefore called deoxy-sphingoid bases (DSBs). The two 
identified metabolites originate from the conjugation of palmitoyl-CoA with alanine and 
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glycine instead of serine. This reaction would result in the formation of the two atypical 
sphingolipids with the lack of the hydroxyl and hydroxymethyl groups at C1 (Fig.24). 
 
Fig. 24: (A) Products of the SPT reaction using serine, alanine, or glycine as substrates. The conjugation of 
palmitoyl-CoA with alanine and glycine leads to the formation of the two DSBs: m18:0 and m17:0. (B) Chemical 
structure of the DSBs. The numbers of hydroxyls are designated by m (for mono-) and d (for di-) followed by the 
number of carbons. The second number indicates the double bonds. For example, d18:0 stands for sphinganine, and 
d18:1 stands for sphingosine. All shown metabolites were also found in the N-acetylated form. 
 
Indeed, when HEK133W and HEK133Y cells treated with alanine (10 mM) and glycine 
(10 mM), and the de novo synthesis is blocked with FB1, the levels of 1-deoxy-
sphinganine and 1-deoxymethyl-sphinganine were increased, respectively, 4-fold and 
10-fold suggesting that the HSAN1 mutations induce a shift in the substrate affinity of 
SPT from serine toward alanine and glycine (Fig.25).             
 
Fig. 25: (C) Accumulation of m18:0 and m17:0 in HEKC133W cells after supplementing the culture medium with 
alanine or glycine. HEKC133W cells were cultured using either standard medium (-) or medium that was 
supplemented with 10mM alanine (-ala) or 10mM glycine (-gly). De novo synthesis was blocked with FB1 for 24 h, 
and the accumulated lipids were analyzed by LC-MS. (D) Accumulation of DSB in HEK cells expressing mutant 
forms of SPT. HEKempty, HEKL1, HEKC133W, and HEKC133Y cells were treated with FB1 for 24 h, and the 
extracted lipids were quantified by LC-MS. Error bars in C and D indicate S.E. p values ≤ 0.01 were labeled with **. 
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DSBs are successively metabolized but not in the classical pathway. The lack of the 
hydroxyl and hydroxymethyl groups inhibit the formation of higher substituted 
sphingolipids, such as phospho- and glycosphingolipids, but these substrate can’t be 
degraded by the classical pathway because of the  inability to format a phosphoester 
bond at C1. Furthermore, DSBs are substrate for ceramide synthase, N-acylated and also 
desaturated by ceramide desaturase (DES), which results in the formation of deoxy-
ceramide and deoxy-methyl-ceramide (demonstrated by the elevated levels of deoxy-
sfingosine and deoxy-methyl-sphingosine in lipid extraction). Indeed, in the human 
HSAN 1 plasma higher levels of unsaturated DSBs (than saturated type) has been 
detected. Furthermore, the highest DSBs levels are correlates with the most severe 
HSAN1 phenotype while moderately elevated DSBs levels are correlated with moderate 
HSAN 1 phenotype. Quantitative analyses revealed a dose-dependent effect of DSBs on 
neuritis growth and also in a significant dose-dependent reduction of neuritis length. 
Indeed, when DRG (dorsal root ganglia) cultured neurons are added of SA (1 µM), 1-
deoxy-sphinganine (1 µM) and 1-deoxy-methylsphinganine (1 µM) it results in a 
reduction of cells that presents 1 or more neuritis (30% reduction) compared with the 
control take place suggesting that DSBs disturb neuritis formation. Furthermore, when 
DSBs are added to SA cultured cell, it results in significant regression of the already 
formed neuritis. Immune-fluorescence analyses suggest that DSBs change the stability 
and dynamics of neurofilament formation. Indeed, actin and neurofilament are co-
locatizated over the whole length of the neuritis in neurons which are cultured in the 
presence of SA while the neuritis of neurons that are cultured in the presence of 1-
deoxy-sphinganine has a clearly disturbed cytoskeletal structure. The neurofilament 
straining is significantly shortened and only partly co-localized with the actin, whereas 
the actin is detected over the whole length of the neuritis suggesting that the 
pathological mechanism in HSAN1 is the accumulation of these neurotoxic metabolites 
rather than the reduced de novo sphingolipid synthesis
95
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8. Melanoma 
Melanoma is the most common and the most aggressive skin cancer originating from 
neural crest–derived melanocytes, pigment cells present normally in the epidermis and 
sometimes in the dermis. Melanoma can metastasize to any organ, the brain being a 
particularly common site. Metastatic melanoma is generally incurable, with survival in 
patients with visceral metastases generally less than 1 year. This is mainly due to 
multidrug and radiotherapy resistance by deregulation of apoptotic pathways. Ceramide 
and sphingosine have been implicated to be lipid signaling molecules in regulation of 
apoptosis, while sphingosine- 1-phosphate has been reported to be a trigger for signal 
transduction pathways of cell proliferation
90
. Ceramide has a central role in both 
apoptotic and mitogenic pathways (especially phosphorylated ceramide/sphingosine) 
and is often generated in response to chemotherapeutics and radiotherapeutics via 
hydrolysis of sphingomyelin by activated sphingomyelinase (SMase)
91,92
. Moreover, an 
increased cellular capacity for ceramide glycosylation has been identified as a multidrug 
resistance mechanism. Indeed, multidrug resistant cell types have been reported to 
display an altered sphingolipid composition, frequently represented by increased level 
of glucosylceramide
93
. Natural products have been proposed as possible treatment for 
multi-drug resistant melanoma. Myriocin, ISP-1 or thermozymocidin, in addition of the 
inhibitor activity of the first step of de novo sphingolipid biosynthesis pathway, which 
reduces the intracellular pool of sphingolipid intermediates, also decreases extracellular 
sphingomyelin, sphingosine-1-phosphate (which has been reported to induce prostate 
cancer cell migration
94,95
 and glycosphingolipids levels
96,97
. Myriocin has been shown to 
inhibit proliferation of a certain IL-2- dependent mouse cytotoxic T-cell line
98
. 
Treatment of B16F10 cells (originating from a murine malignant melanoma) with 
myriocin cause cell numbers decrease and inhibition of cell proliferation by 
approximately 70% compared to that of controls. The inhibition resulted in both 
concentration- and time-dependent relation. Furthermore, cell migration when 
determined by a wound-healing assay result in an inhibition by 69% to 73% compared 
to those of concurrent controls. Incorporation of [
3
H] thymidine in B16F10 cells result 
decreased when cultured with 10 µM myriocin suggest a decreased DNA synthesis of 
about 50% compared to control. DNA synthesis appears correlated with cell population 
growth in a time-dependent manner. When analyzed, accumulation of cells in G2 /M 
occurred after addition of myriocin. The percentage of B16F10 cells, treated with 
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myriocin, in the G2/M phase appear greatly increased in comparison with control 
suggesting that myriocin inhibit cell proliferation by G2/M arrest during cell cycle 
progression. Myriocin-induced inhibition of cell proliferation may occur through both 
inhibition of cdc25C and activation of p53 and p21
waf1
 
/ cip1
 signalling pathways leading 
to cell cycle arrest at G2/M phase. Notably, no cell death for apoptosis occurs. 
The mechanism myriocin induce cell cycle arrest by, is through regulation of the 
activity of the protein controlling cell cycle. Cdc2 and cyclin B1 are essential for the 
regulation of the crossing from G2 to M phases. These proteins are usually inactivated 
through phosphorylation by Weel’s protein-kinase, whereas de-phosphorilation causes 
activation and cell cycle promotion. The tumor suppressor protein p53 arrest the cell 
cycle in G2/M phase after DNA damage, hypoxia and expression of mutant oncogenes 
(Fig.26)
99
. 
 
Fig. 26: Proposed signaling pathways involved in cell cycle arrest induced by myriocin in malignant melanoma cells. 
 
In B16F10 cells treated with myriocin, the levels of p53 result increased that bring to 
activation or decrease transcription of several genes involved in its upstream control. 
Indeed, one of the p53 transcription target cyclin-dependent kinase inhibitor (CIK) p21
waf1 /
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cip1
 found overexpressed in B16F10 cells treated with myriocin, binding to and inhibiting 
activity of the cyclin B1/cdc2 with consequently cell cycle arrest in G2 phase
100
. 
Chk2 (checkpoint kinase 2) and PLK1 (serine/threonine-protein kinase) can modulate 
Cdc25 by stimulating the Cdc2/ciclin B1 complex, directly inhibited by Weel’s protein 
kinase
101
. The levels of these proteins in B16F10 cells appear to be not altered in 
comparison with control suggest that the myriocin-induced cell cycle arrest occurr through 
the p53- p21 signalling pathway
102
. In addition, when treated with caffeine, well known to 
stimulate several phosphatase leading to de-phosphorilation of p53, the B16F10 cells 
treated with myriocin revealed a decreased of p53, p-p53 and p21
waf1
 
/ cip1
. However, 
caffeine did not reverse the effect of myriocin on cell proliferation. 
The decreased of ceramide levels and the reduced level of cdc2/ciclin B1 in B16F10 
cells was reversed by adding C8-ceramide, suggesting the essential role of endogenous 
sphingolipids in the tumor growth. Myriocin decrease ERK phosphorylation, well-
known to stimulate tumourigenesis, and modulate PKC activity
103
. Furthermore, 
myriocin decrease the level of gangliosides GD3, highly expressed in malignant 
melanoma cells and enhances their properties in mice and this could play role in the 
anti-proliferative activity of myriocin in B16F10 cells
104
.  
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INTRODUCTION TO  
EXPERIMENTAL PART 
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Sphingolipids (SLs) are components of membrane lipid layer ubiquitously distributed in 
mammalian, bacteria and fungi cells. SLs metabolites modulate different cellular events, 
such as proliferation, differentiation and apoptosis. Therefore, SLs metabolism 
modulators may represent powerful tools in biochemical and pharmacological studies. 
The first step of sphingolipid biosynthesis is represented by the condensation of L-
serine and palmitoyl-CoA, catalysed by serine palmitoyltransferase (SPT). Several 
natural compounds have been found to be powerful SPT inhibitors. However, these 
substances have structure similarities to the sphingolipid metabolite sphingosine, which 
modulate several biochemical events in cellular metabolism. Several natural products 
have been identified as SPT inhibitors even if these compounds are able to interfere in 
other biochemical pathways. L-cycloserine and β-chloro-L–alanine have been studied as 
SPT inhibitors in intact cells. Unfortunately these compounds inhibit several PLP-
dependent enzymes avoiding a clinical use. Natural compounds as myriocin and 
viridofungines have been studied as powerful SPT inhibitors. Myriocin inhibits 
sphingolipids biosynthesis through inhibition of SPT rate and furthermore, Myriocin is 
a potent immunosuppressant (more than 100 fold than cycloserine according to several 
studies) which may preclude a long term using in chronic pathologies. However, 
myriocin has been revealed an important tool which allowes investigation of SPT as 
new therapeutic target for treatment of atherosclerosis and retinitis pigmentosa (RP). 
Viridofungines are natural SPT inhibitors less active than myriocin but these derivatives 
are able to inhibit several enzymes susceptible to tri- and di-carbossilic acids like 
squalene synthase.
34 Looking at non-natural SPT inhibitors the only data reported are 
represented by a patent
111
 developed by Bolton and colleagues. Neurodegenerative 
disease treatment represent a huge focus of pharmaceutical research. In the last few 
years SPT role as innovative target in neurodegenerative disease treatment has been 
highlighted.  
Our research group, have developed different compounds as new SPT inhibitors. 
Referring to literature compounds of formula 1 (described in the patent
111
) have been 
evaluated as starting point to advance new SPT inhibitor. Several structural analogues 
(not present in the patent) have been synthesized. Biological data showed interesting 
indications of substituent’s type and position on the central core. One of the most 
interesting derivatives obtained is represented by compound 2 which have inhibitory 
activity in the order of micromolar range. The aim of the present thesis work, was to 
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evaluated  the  influence of central core (2-oxo-benzimidazole) in the inhibitor-enzyme 
interaction. During thesis work have been developed compound of general formula 3, 4, 
5 and 6 (Fig.27). Such modifications have been mainly directed toward the oxo-
benzimidazole core in order to verify electronic and conformational influences of the 
bicycle nucleus in interaction with enzyme.        
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Results and discussion 
The derivatives of general formula 3 (Scheme 1) were synthesized starting from 4-
chloro-3-nitro-benzonitrile which is subjected to a SNAr with 4-amino-1-Boc piperidine, 
leading to 7. In order to reduce reaction time, the synthetic procedures was developed 
using a microwave system obtaining very good yields (90 %) which reduced with H2 
and Pd/C to obtain derivative 8  which subsequently was cyclizated in presence of 
trimethyl ortoformate at 148 °C for 1h to obtain the desired compound 9. The crude 
mixture was purified by flash chromatography leading to 60% yield. To improve 
reaction yield , derivative 8 was cyclizated using a  microwave system in presence of 
trimethyl ortoformate and formic acid at 180°C for 40 minutes. After flash-
chromatography purification the desired compound 9 was obtained in good yields (75 
%). Then the carbammic group of compound 9 has been hydrolyzed in acidic 
environment using a trifluoroacetic acid and dichloromethane mixture (65% yields) or 
using a solution of hydrochloric acid in hydro-alcoholic solution (80% yields) leading to 
compound 10. The desired compound was obtained after neutralization of the crude 
mixture as  precipitate. Moreover a synthetic procedure involving direct cyclization of 8 
with formic acid to obtain compound 10 has performed. Unfortunately purification of 
the crude mixture was difficult in relation to compound solubility. 
Compound 10 was reacted with p-chlorophenylacetyl chloride or 2-bromo-p-
chloroacetophenone in order to obtain compounds 11a and 11b respectively. The 
derivative 11a was obtained in good yields (65%) after purification by flash-
chromatography.  Conversely, the crude product of 11b was very complex and the 
desired compound was obtained in very low yields (18%).  Unfortunately subsequent 
modification of the procedure has not improved reaction yields. As described in 
literature, the cyano-derivatives 11a and 11b were converted to compounds 12a and 
12b after reaction with azido(trimethyl)silane and tetra- N-butylamino fluoride (TBAF) 
at 130°C for 48h
112
. The final compound 12a was filtered off after treatment of the 
crude mixture with a 2M aqueous solution of hydrochloric acid (40% yields) without 
needs of further purification process. Compound 12b was subjected to different 
purification procedures (flash-chromatography, crystallization etc.) without success. 
Nowadays, procedures to obtain the compound 11b are in progress.  
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a: R= p-chlorophenylacetyl   b: R= p-chlorophenylacyl 
 
Reagents and conditions: (i) DIPEA, DMF, 4-amino-1-Boc-piperidine, microwave, 130°C, 15 min, 5 
bar; (ii) THF, H2, EtOH, Pd/C, r.t., 4h; (iii) toluene, trimethyl ortoformiate, formic acid, microwave, 
180°C, 40 minutes, 9 bar; (iv) hydrochloric acid, ethyl acetate; methanol, r.t. 1h; (v) a: DMF, THF, 
triethylamine, p-chlororphenylacetyl chloride, r.t. 2h; b: DMF, THF, triethylamine, 2-bromo-p-
chloroacetophenone r.t. 2h; (vi) azido(trimethyl)silane, TBAF, N2, 120°C, 48h. 
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4-chloro-3-nitro-benzonitrile 
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Different synthetic strategies were evaluated to synthesized compounds of general 
formula 4, 5 and 6 and it was identified as building block molecule the indoline 
derivatives 14. This molecule is an useful tool to synthesize indole derivatives 
substituted in position 1 with a piperidine ring whose insertion is diffucult to obtain 
using other synthetic approach (such as reaction between the indole core and a 4-
methylsulfonyloxy-pipertidine derivative)
113
. As well as indole system, the insertion of 
piperidine group on the isatine core is difficult to perform, whereas direct oxidation of 
substituted indole lead to isatine derivatives in good yield
114
. On the basis of these 
observations, a synthetic strategy characterized by the use of 14 as building block has 
been pursued (Fig. 28). 
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A commercial available indoline was reacted (Scheme 2) with bromine in 
dichloromethane at -30°C leading to the 5-bromo-indoline compound 13 (accordingly 
with literature)
115
.  
14 
4 
5 
6 
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The crude mixture was purified by flash-chromatography (70% yield ). Afterwards, a 
direct reductive amination reaction between the derivative 13 and 1-Boc-4-piperidone 
has been performed. The immine produced was reduced in situ by addiction of sodium 
triacetoxyborohydride. This reductive agent was selected in order to avoid reduction of 
the ketone and formation of toxic by product (produced by reducing agent such as 
sodium cyanoborohydride)
116
. The desired compound 14 was obtained in good yields 
(80%) as a white powder after purification by flash-chromatography. As previously 
described, the piperidine protective group (Boc) of 14 was hydrolyzed in acidic 
environment and the pure product was obtained after alcalinization as precipitate which 
was collected, identified and characterized as 15. Finally, 15 reacted with p-
chlorophenylacetyl chloride or 2-bromo-p-chloroacetophenone in presence of 
triethylamine to obtain compound 16a and 16b respectively. Purification of crude 
mixtures showed the same problem noticed for 12a and 12b. The derivative 16a was 
purified by flash chromatography whereas the derivative 16b was a complex mixture 
hardly purified. Procedures to obtain the desired compound 16b are currently in 
progress. [The synthetic procedures have revealed that the b (p-chloroacetophenyl) 
substituent makes the compounds difficult to purify and characterize: for this reason 
synthetic procedure characterized by use of the substituent a (p-chlorophenylacetyl) 
only has been pursued]. 
Subsequently, accordingly with literature
117
 the bromo-derivative 14 was converted to 
the cyano-derivative 17 avoiding the use of toxic reagents such as sodium cyanide: it 
was heated in presence of potassium hexacyanoferrate(II) trihydrate, 
tetrakis(triphenylphosphine)palladium(0), and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) in a mixture of tert-butanol and water under nitrogen atmosphere to obtain the 
compound 17 which was  purified by flash-chromatography (75% yields) (Scheme 2). 
The compound 18 was obtained applying the same reaction conditions and purification 
procedures used to obtain 15. Compound 18 was subsequently reacted with p-
chlorophenylacetyl chloride in presence of triethylamine. The crude product was 
purified by flash-chromatography to yield the desired compound 19a (60%) whose 
inhibitory activity was evaluated. Reaction of derivative 19a with azido(trimethy)silane 
and TBAF in nitrogen atmosphere led compound 20a (Scheme 2).  
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a: R= p-chlorophenylacetyl    b: R= p-chlorophenylacyl 
 
Reagents and conditions: (i) dichloromethane, bromine, -30°C, 2h; (ii) dichloromethane, 1-Boc-4-
piperidone, acetic acid (glacial), sodium triacetoxyboronhydride, 0°C, 15 minutes; r.t. 3h; (iii) 
hydrochloric acid (32%), ethyl acetate, methanol, 4h; (iv) a: DMF, THF, p-chlorophenylacetyl chloride, 
triethylamine, r.t., 3h, b: DMF, THF, triethylamine , 2-Bromo-p-chloroacetophenone, r.t., 3h. (v) 
hydrochloric acid (32%), ethyl acetate, methanol, 4h; (vi) hydrochloric acid (32%), ethyl acetate, 
methanol, 4h; (vii) DMF, THF, p-chlorophenylacetyl chloride, triethylamine, r.t., 3h; (viii) 
azido(trimethyl)silane, TBAF, 120°C, 48h. 
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In order to obtain indole derivatives of formula 5 (Scheme 3), compound 14 was 
oxidized using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) at 0°C for 3 h  
leading to the compound 21 as described in letterature
118
. The pure product was 
obtained after purification by flash-chromatography in very good yield (90%). As well 
as performed for indoline derivatives, indole derivatives substituted with different 
functional group in position 5 were synthesised. As described previously, 21 was 
hydrolyzed to 22 and reacted with p-chlorophenylacetyl chloride; the crude mixture was 
purified by flash chromatography leading to compound 23a (60% yields). Moreover, 
compound 21 was subjected to the same synthetic iter applied to obtain compounds 17 
(scheme 2) to obtain the cyano-indole derivatives 24 which was deprotected leading to 
compound 25 (Scheme 3). Subsequently, applying the same reaction conditions as 
described previously in scheme 2, starting from compound 25, compounds 26a and 27a 
were obtained consequently. These compounds were purified by flash-chromatography 
(26a) or precipitation (27a).  
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R= p-Chlorophenylacetyl   
 
Reagents and conditions : (i) THF, DDQ, 0°C, 3h; (ii) ethyl acetate, methanol; hydrochloric acid (32%), 
r.t., 2h; (iii) DMF, THF, triethylamine, p-chlorophenylacetyl chloride, r.t., 12h; (iv) potassium 
hexacyanoferrate(II) trihydrate, TPP-Pd; tert-butanol/ water, DBU, r.t. 10 min, 85°C, 24h; (v) ethyl 
acetate, methanol; hydrochloric acid 32 %, 30°C, 3h (vi) DMF, THF, triethylamine, p-chlorophenylacetyl 
chloride, r.t., 12h; (vii) azido(trimethyl)silane, TBAF, 120°C, 48h. 
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To synthesize the isatine derivatives of general formula 6, the 5-bromo-indole 
derivative 21 was oxidized with chromium oxide (VI) at room temperature for 2h 
(Scheme 4).
 
After neutralization and purification by flash chromatography of the 
reaction mixture the desired compound 28 was obtained as orange powder (28% yields). 
The bromo-isatine derivative 28 was heated in presence of potassium 
hexacyanoferrate(II) trihydrate, tetrakis(triphenylphosphine)palladium(0), and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in a mixture of tert-butanol and water under 
nitrogen atmosphere to obtain the compound 29. Unfortunately, a complex reaction 
mixture was obtained not allowing isolation of the desired compound. Purification 
procedures to obtain the isatine derivative 29, as precursor for final compounds of 
general formula 6a are still under development. 
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R= p-Chlorophenylacetyl  
 
Reagents and conditions : (i) acetone, acetic acid, water, chromium(VI) oxide, r.t., 2h; (ii) potassium 
hexacyanoferrate(II) trihydrate, TPP-Pd; tert-butanol/ water, DBU, r.t. 10 minutes; 85°C, 24h. 
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The inhibitory activity on SPT of the final products was evaluated using a radioactive 
assay at the research lab of Prof. Ghidoni (Lab Biochem & Mol Biol, San Paolo 
Medical School, University of Milan). The enzyme source used was a HEK293 cell 
lysate. Each compound was tested in final concentration of 50 M (Table 1). The 
reference compound 2 showed higher inhibitory activity (74% at 50M) than all the 
developed compounds. 
 
TABLE 1 
 
Table 1 
Comp. R2  R1  Formula  
% 
Inhibition  
11a  CN  p-chlorophenylacetyl  3  0%  
12a  Tetrazole  p-chlorophenylacetyl  3  33%  
11b  CN  p-chloroacetophenyl  3  57%  
16a  Br  p-chlorophenylacetyl  4  0%  
19a CN  p-chlorophenylacetyl  4  1%  
20a Tetrazole  p-chlorophenylacetyl  4  31%  
23a Br  p-chlorophenylacetyl  5      14,29%* 
26a CN  p-chlorophenylacetyl  5       25,92%* 
27a Tetrazole  p-chlorophenylacetyl  5       29,04%* 
*Preliminary data. 
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EQUIPMENT USED  
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• Melting points were determined on a Kofler hot stage apparatus and are 
uncorrected. 
• 1H NMR and 13C NMR spectra were recorded with a Bruker AC-200 
spectrometer in δ unit from TMS as an internal standard. 
• Analytical TLC was carried out on Merck 0.2 mm precoated silica-gel glass 
plates (60 F-254) and location of spots was detected by illumination with a UV lamp. 
• Microwave used was a Biotage Initiator EXP EU, 355301, 11443-11X, 400W, 
2450 MHz. 
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EXPERIMENTAL PART  
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 tert-Butyl 4-(2-nitro-4-cyanophenylamino)-piperidine-1-carboxylate (7) 
In a microwave vial containing 3.5 mL of N,N-diisopropylaethylamine, (DIPEA, 
d=0.742) and 4 mL of dimethylformamide (DMF), 1.826 g (10 mmol) of 4-chloro-3-
nitrobenzonitrile were dissolved. Afterwards, 2.4 g of 4-amino-1-Boc-piperidine were 
added and the mixture was placed in microwave device. Reaction conditions: 15 
minutes; 130°C; 5 bar. After cooling, the reaction mixture was added of 50 mL of ethyl 
acetate and 10 mL of tetrahydrofuran (THF). The organic layer was washed with 0.5 M 
solution of hydrochloric acid (2x40 mL) and brine in a separatory funnel. The organic 
layer was dried over magnesium sulfate, filtrated and evaporated in vacuo leading to the 
desired compound as a yellow powder.  
The titled compound was obtained as a pure product crystallizing achieved using 
toluene. 
Yield: 90% 
M.W.: 346.38; C22H22O4N4 
Mp: 143-145°C 
1H NMR (DMSO, 200 MHz):  δ 8.52 (s, 1H, Ar), 8.25-8.21 (m. 1H, Ar), 7.86-7.82 (m, 
1H, Ar), 7.35-7.30 (m, 1H), 3.95-3.88 (m, 2H), 3.1-2.8 (m, 2H), 1.96-1.85 (m, 2H), 
1.55-1.48 (m, 9H, Boc) 
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tert-Butyl 4-(2-amino-4-cyanophenylamino)-1-piperidinecarboxylate (8) 
An amount of 1.21 g (3.49 mmol) of tert-butyl 4-(2-nitro-4-cyanophenylamino)-1-
piperidinecarboxylate (7) was solubilized in 120 mL of a solution of THF (5%) and 
absolute ethanol (95%). The solution obtained was added of Pd/C, placed under 
hydrogen and stirred at room temperature for 4h. Afterwards, the solution was filtrated 
on a silica pad and washed with ethyl acetate (100 mL). The organic phase was 
eliminated in vacuum leading to a white powder. 
The title compound was obtained crystallized using isopropanol. 
 
Yield: 90% 
M.W.: 316.4; C24H2402N4 
Mp: 160°-162° C 
1
H NMR (CDCl3, 200 MHz): 7.17-7.13 (d, 1H, Ar), 6.96 (s, 1H, Ar), 6.63-6.58 (m, 1H, 
Ar), 4.106-3.92 (m, 4H), 3.47-3.29 (m, 2H), 3.02-2.96 (m, 2H), 2.08- 2.02 (m, 2H), 1.6-
1.26 (m, 9H, Boc). 
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tert-Butyl 4-(5-cyano-1H-benzimidazol-1-yl)piperidine-1-carboxylate (9) 
Method A 
An amount of 0.632 g (2 mmol) of tert-butyl 4-(2-amino-4-cyanophenylamino)-1-
piperidinecarboxylate (8) was solubilized in 5 mL of trimethyl ortoformiate (45 mmol, 
d=0.97 g/mL). The solution was heated at 148°C (reflux) for 1h. Afterwards, the 
solution was cooled and the solvent evaporated in vacuum. The crude mixture was 
purified by flash chromatography (eluent ethyl acetate). The combined fractions were 
evaporated leading to the pure product as a white powder. 
Yield A: 60 % 
 
Method B 
A solution of 0.88 g (2.78 mmol) of tert-butyl 4-[(2-amino-4-
cyanophenyl)amino]piperidine-1-carboxylate (8) in toluene (5 mL) was added of 3.7 
mL (27.8 mmol, d=0.97 g/mL) of trimethyl ortoformiate and 10 μL (0.265 mmol, 
d=1.22 g/mL) of formic acid. The solution was placed in microwave equipment (180°C; 
40 minutes and 9 bar). After cooling, the reaction was added of water and extracted with 
toluene. The organic layer was dried over magnesium sulfate and evaporated in vacuum. 
The crude mixture was purified by flash chromatography (ethyl acetate and n–hexane; 
5:1). The combined fractions were evaporated leading to the pure product as a white 
powder. 
Yield B: 75 % 
M.W.: 326.39; C18H22O2N4 
Mp: 115-116°C 
1
H-NMR (200 MHz CDCl3):  δ 8.15 (s, 1H, N=CH-N); δ 8.11 (s, 1H, Ar); δ 7.55 (dd, 
2H, Ar), δ 4.39 (m, 4H), δ  3.0-2.95 (t, 2H), δ 2.95 (t, 2H), δ 1.50 (s, 9H, Boc). 
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1-(piperidin-4-yl)-1H-benzimidazole-5-carbonitrile (10) 
Method A: 
An amount of 0.51 g (1.56 mmol) of tert-butyl 4-(5-cyano-1H-benzimidazol-1-
yl)piperidine-1-carboxylate (9) was solubilized in 25 mL of ethyl acetate and methanol 
mixture (1:1). The solution was added, of 6 mL of a 32% solution of hydrochloric acid. 
After 1h the solution was concentrated in vacuum and the residue was added of a 
saturated solution of sodium bicarbonate until pH=8. The obtained solution was 
extracted with chloroform and the organic layer was dried over magnesium sulfate, 
filtrated and solvent evaporated in vacuum. The title compound was collected as a white 
powder. 
Yield A: 65 % 
Method B: 
0.326 g (1 mmol) of tert-butyl 4-(5-cyano-1H-benzimidazol-1-yl)-piperidine-1-
carboxylate (9) was solubilized in 10 mL of dichloromethane. After that, 0.8 mL of 
trifluoroacetic acid was added and the reaction stirred at room temperature. After 2h the 
solution was concentrated in vacuum, and the residue added a saturated solution of 
sodium bicarbonate until pH=8. The obtained solution was extracted with chloroform 
and the organic layer was dried over magnesium sulfate, filtrated and solvent eliminated 
in vacuum. The title compound was collected as a white powder after dried over in 
vacuum overnight. 
Yield B: 80 % 
M.W.:  226. 28; C13H14N4 
M.p.: 170°-172°C  
1
H-NMR: DMSO δ 8.732 (s, 2H, NHH, br), 8.55 (s, 1H, N=CH-N) 7.95(d, 1H, Ar), δ 
7.912 (d, 1H, Ar), 4.80 (m, 1H, N-CHCC), 3.52 (m, 2H), 3.18 (m, 2H), δ 2.49 (m, 2H), 
2.23 (m, 2H); 
13
C-NMR: DMSO δ 169.3 (C=O), 143.7 (C), 142.7(CH), 135.8 (C), 133.3 (C), 133.2 
(C), 130.2 (CH2), 129.3 (CH2), 126.5 (CH), 126.1 (CH), 119.7 ( C ), 111.1 (CN), 106.3 
(C ), 54.3 (CH2), 45.5 (CH ), 41.5 ( CH ), 40.6 (CH2), 32.7 (CH), 31.9 (CH). 
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1-(1-(2-(p-chlorophenyl)acetyl)piperidin-4-yl)-1H-benzimidazole-5-carbonitrile 
(11a) 
An amount of 0.23 g (1.0 mmol) of 1-(piperidin-4-yl)-1H-benzimidazole-5-carbonitrile 
(10) was solubilized in 2 mL of DMF and 4 mL of THF. The mixture was stirred at 
room temperature and added of 280 L (2 mmol, d=0.726 g/mL) of triethylamine and 
176 L (1.2 mmol, d=1.292 g/mL) of 4’-chlorophenilacetyl chloride. After 2h the 
mixture was concentrated in vacuum and cold water was added to the residue. The crude 
product was extracted with chloroform which was dried over magnesium sulfate and 
concentrated in vacuum. The residue (302 mg) was purified using a BUCHI Sepacore 
chromatography (10:0.05 ethyl acetate/acetonitrile). The combined fractions were 
evaporated leading to the pure product as a white powder. 
Yield: 65 % 
M.W.:  377.87; C21H19N3Cl 
M.P.: 177-179 °C 
1
H-NMR (200 MHz, CDCl3): δ 8.15 (s, 1H, N=CH-N), δ 8.03 (s, 1H, Ar), δ 7.58-7.54 
(d, 1H, Ar), δ 7.43-7.21 (m, 7H, Ar), 4.98 (d, 1H, N-CHCC), 4.43-4.37 (m, 1H), 4.14-
4.07 (m, 1H), 3.78 (s, 2H),  3.51-3.44 (m, 1H), 3.31-3.18 (m, 1H), 2.85-2.72 (m, 1H), 
2.19-1.71 (m, 9H), 1.25-1.18 (m, 2H). 
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1-{1-[(p-Chlorobenzoyl)methyl]piperidin-4-yl}-1H-benzimidazole-5-carbonitrile 
(11b) 
0.230 g (1.0 mmol) of 1-(piperidin-4-yl)-1H-benzimidazole-5-carbonitrile (10) were 
dissolved in 2 mL of DMF. The obtained solution was added of 280 L (2 mmol, 
d=0.726 g/mL) of triethylamine and 2 mL of a solution of 2-bromo-p-
chloroacetophenone (0.25 mg) in THF  and stirred at room temperature. After 2h the 
reaction mixture was concentrated in vacuum. The residue was added of cold water and 
extracted with dichloromethane. The solvent was removed in vacuum and the crude 
mixture was dissolved in methanol, adsorbed on silica gel and purified in flash 
chromatography (ethyl acetate/n-hexane 1:7). The combined fractions were evaporated 
leading to the pure product as a white powder. 
Yield: 18 % 
M.W.: 378.85; C21H19ON4Cl 
M.P.: 157°-159° (crystalized in isopropanol and obtained) 
1
H NMR (200 MHz CDCl3): δ 8.16 (s. 1H, Ar), 7.99-7.90 (m, 1H, Ar), 7.55-7.26 (m, 
5H, Ar), 4.67-4.66 (m, 1H), 3.91 (s, 2H, CH2), 3.25-3.19 (m, 2H), 2.52-2.05 (m, 3H). 
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2-(p-chlorophenyl)-1-{4-[5-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl]piperidin-1-
yl}ethanone (12a) 
In a screw cap vial, 0.151 g (0.4 mmol) 1-(1-(2-(p-chlorophenyl)acetyl)piperidin-4-yl)-
1H-benzimidazole-5-carbonitrile (11a) were added and stirred under nitrogen 
atmosphere. Then 110 L (0.4 mmol, d=0.868 g/mL) of azido(trimethyl)silane and 200 
L (0.2 mmol) of tetra-n-butylammonium floride (TBAF) in THF. Then, the mixture 
was heated at 120°C for 48h. The crude mixture (brown solid) was cooled at room 
temperature and washed with a 2M aqueous solution of hydrochloric acid (3 X 5 mL) 
and ice leading to a yellow precipitate which was filtered and washed with water. The 
titled compound was crystallized using acetonitrile leading to a yellow powder. 
Yield: 40 % 
M.W.: 421.89; C21H20ON7Cl  
Mp: 225°-227° C 
1
H-NMR: DMSO δ 9.20 (s, 1H, N=CH), 8.50 (s, 1H, Ar), 8.16-8.15 (m, 2H, Ar), 7.40-
7.30 (m, 4H, Ar), 4.90-4.50 (m, 1H, N-CH), 4.20-4.10 (m, 1H), 3.90-3.80 (s, 2H, CH2), 
3.40-3.10 (m, 2H) 2.79-2.73 (m, 2H), 2.13-1.94 (m, 4H). 
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1-(p-chlorophenyl)-2-{4-[5-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl]piperidin-1-
yl}ethanone (12b) 
In a screw cap vial, 0.10 g (0.26 mmol) of 1-{1-[2-(p-chlorophenyl)-2-
oxoethyl]piperidin-4-yl}-1H-benzimidazole-5-carbonitrile (11b) were added of 70 L  
of azido(trimethyl)silane (0.52 mmol, d=0.868 g/mL) and 130 L (0.13 mmol) of 
tetrabutylamino floride (TBAF) in THF and stirred under nitrogen atmosphere. The 
mixture was heated at 120°C for 48h. Then the crude mixture (brown solid) was cooled 
at room temperature and washed with a 2M aqueous solution of hydrochloric acid (3 X 
5 mL) leading to a yellow powder. The solid product was filtered and washed with 
water.  
The title compound was hardly to purify. 
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 5-Bromoindoline (13) 
1.9 mL (16.8 mmol, d=1.063 g/ml) of indoline were solubilized in 120 mL of 
dichloromethane and cooled at -30 °C. 40 mL (16.8 mmol, d=3.119 g/ml) of a bromine 
solution in dichloromethane were added dropwise in 30 min. The reaction was stirred 
for further 2 h at -30°C. Then a solution of 0.1 N sodium thiosulfate (2x40 mL) was 
added in order to quench the reaction. The organic phase was dried over magnesium 
sulfate, filtered and evaporated in vacuum. The crude mixture was purified by flash 
chromatography (5:1; n-hexane/ethyl acetate). The combined fractions were evaporated 
in vacuum leading to the pure product as a yellow powder. 
Yield: 70% 
M.W.: 198.06; C8H8NBr 
M.P.: 39°-40°C 
1
H NMR (200 MHz DMSO):  δ 7.12 (s, 1H, Ar), 7.03 (d, 1H, Ar), 6.99 (d, 1H, Ar), 
6.44-6.39 (s, br, 1H, NH), 3.64(t, 2H, CH2), 3.14(t, 2H, CH2); 
1
H NMR (200 MHz CDCl3): δ 7.21 (s, 1H, Ar), 7.09 (dd, 1H, Ar), 6.50(d, 1H, Ar), 3.57 
(t, 3H, CH2, NH), 3.02 (t, 2H, CH2); 
13C NMR (200 MHz DMSO):  δ 151.20 (C), 131.12 (C), 128.66 (CH), 126.22 (CH), 
109.05 (CH), 106.50 (C), 46.03 (CH2), 28.49(CH2). 
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tert-Butyl 4-(5-bromo-indolin-1-yl)piperidine-1-carboxylate (14) 
An amount of 1.72 g (8.9 mmol) of 5-bromoindoline (13) were dissolved in 20 mL of 
dichloromethane and cooled at 0°C under stirring. Then 1.95 g (9.79 mmol, 1.1 eq) of 
1-Boc-4-piperidone, 1.3 mL of glacial acetic acid and 2.83 g (13.35 mmol, 1.5 eq) of 
sodium triacetoxy borohydride were added. After 15 min the reaction was kept at room 
temperature and stirred for further 3h. Then the reaction was stopped by addiction of 10 
mL of saturated solution of sodium bicarbonate. After the separation from the organic 
phase, the aqueous layer was extracted with dichloromethane. The organic phases were 
collected, dried over magnesium sulfate and the solvent was evaporated in vacuum. The 
crude mixture was purified by flash chromatography (5:1, n-hexane/ethyl acetate). The 
combined fractions were evaporated leading to the pure product as a white powder. 
Yield: 80% 
M.W.: 381; C18H25O2N2 
M.P.: 91°-93 °C 
1
H NMR (200 MHz CDCl3):  δ 7.14 (s, 1H, Ar), 7.11 (d, 1H, Ar), 6.28 (d, 1H, Ar), 
4.27-4.22 (m, 1H, CH), 3.36 (tr, 2H, CH), 2.97-2.76 (m, 4H, CH), 1.79-1.74 (m, 3H, 
CH), 1.64-1.48 (s, 12H, CH3);  
1
H NMR (200 MHz DMSO):  δ 7.11-7.07(m, 2H, Ar), 6.44-6.40 (d, 1H, Ar), 4.06-3.99 
(m, 1H, CH), 3.60-3.33 (m, 1H, CH), 2.89-2.81 (m, 4H, CH), 1.65-1.60(m, 3H, CH), 
1.47-1.22 (m, 13H, CH); 
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5-Bromo-1-(piperidin-4-yl)-indoline (15) 
A mixture of 1.143 g (3 mmol) of tert-butyl 4-(5-bromo-indolin-1-yl)piperidine-1-
carboxylate (14) were solubilized in 8 mL of ethyl acetate/methanol (1:1) and 2 mL of 
hydrochloric acid 32 % and stirred at room temperature. After 4 h a saturated solution 
of sodium bicarbonate (until pH=8) was added obtaining a precipitate. The solid was 
filtered in vacuum and dryed overnight. The titled compound was collected as white 
powder. 
Yield: 90% 
M.W.: 280.188; C13H17N2Br 
M.P.: 180-182°C 
1H NMR (200 MHz, DMSO): δ 8.97 (br, NH), 7.14(s, 1H, Ar), 7.10 (dd, 1H, Ar), 6.49 
(dd, 1H, Ar), 3.70 (m, 1H), 3.35-3.28(m, 6H), 2.93-2.85 (m, 4H), 1.86-1.79 (m, 2H).  
 13C NMR (200 MHz DMSO): δ 149.06 (C), 132.04 (C), 128.77 (CH), 126.40   (CH), 
107.83 (CH), 106.90 (C), 49.02 (CH2), 45.83 (CH), 42.26 (CH2), 26.85 (CH2), 23.49 
(CH2). 
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1-[4-(5-bromo-indolin-1-yl)piperidin-1-yl]-2-(p-chlorophenyl)ethanone(16a) 
0.28 g (1.0 mmol) of 5-bromo-1-(piperidin-4-yl)-indoline (15) were dissolved in 2 mL 
of DMF and 4 mL of THF and stirred at room temperature. 276 µL (2 mmol, d=0.726 
g/mL) of triethylamine and 176 µL (1.2 mmol) of p-chlorophenylacetyl chloride were 
added. After 3 h the solution was concentrated in vacuum and cold water was added. 
The crude mixture was extracted with dichloromethane, dried over magnesium sulfate, 
filtered and concentrated. The brown semi-solid obtained was purified by flash 
chromatography (,ethyl acetate/n-hexane; 7:2). The combined fractions were evaporated 
leading to the pure product as a yellow light powder. 
Yield: 55 % 
M.W.: 433.756; C20H21ON2BrCl 
M.P.: 143°-145°C 
1
H NMR (200 MHz CDCl3): δ 7.29-7.14 (m, 7H, Ar), 4.83-4.76 (m, 1H), 3.98-3.92 (m, 
1H), 3.73 (s, 2H, CH2), 3.50-2.92 (m, 5H), 2.67.2.61 (m, 1H), 1.86-1.54 (m, 4H).   
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2-[4-(5-bromo-indolin-1-yl)piperidin-1-yl]-1-(p-chlorophenyl)ethanone (16b) 
An amount of 0.28 g (1.0 mmol) of 5-bromo-1-(piperidin-4-yl)-indoline (15) was 
solubilized in acetonitrile (10 mL). The solution was added of 280 µL (2 mmol, 
d=0.727 g/mL) of triethylamine and 2 mL of a solution of 2-bromo-p-
chloroacetophenone (0.467 mg) in THF and stirred at 75 °C (reflux). The mixture was 
put to react overnight. Then the reaction mixture was added of cold water and extracted 
with dichloromethane. The solvent was removed in vacuum. The crude product was 
hard to purify. 
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tert-Butyl 4-(5-cyano-indolin-1-yl)piperidine-1-carboxylate (17) 
A vial was charged with 1.144 g (3 mmol) of tert-butyl 4-(5-bromo-indolin-1-
yl)piperidine-1-carboxylate (8), 0.507 g (1.2 mmol) of potassium ferrocyanide 
trihydrate and 86 mg (0.075 mmol) of tetrakis(triphenylphosphyne)palladium(0). The 
vial was capped, evacuated and backfilled with nitrogen. Subsequently, under nitrogen, 
9 mL of a solution of tert-butanol/ water (1:1) and 110 µL (0.75 mmol, d=1.018 g/mL) 
of 1,5-Diazabiciclo[5.4.0]undec-5-ene (DBU) were added. The vial was stirred 10 min 
at room temperature and then at 85°C (in pre-heated oil bath) for 24 h. The reaction 
mixture was filtered and the cake was rinsed with 20 mL of methanol and 20 mL of 
dichloromethane. The organic solution was dried over magnesium sulfate, filtered and 
evaporated in vacuum. The crude product obtained was solubilized in methanol, 
adsorbed on silica gel and purified by flash chromatography (ethyl acetate). The 
combined fractions were evaporated leading to the pure product as a white powder. 
Yield: 85% 
M.W.: 327.43; C18H25O2N3 
M.P.: 130-132 °C 
1H NMR (200 MHz, DMSO): δ 7.38 (d, 1H, Ar), 7.27 (s, 1H, Ar), 6.54 (d, 1H, Ar), 
4.06-3.99 (m, 2H), 3.69-3.50 (m, 1H), 3.46-3.33 (m, 2H), 2.95-2.80 (m, 4H), 1.661-1.38 
(m, 12H,).  
13C NMR (200 MHz, DMSO): δ 153.42 (C=O), 153.07 (C), 132.53 (CH), 129.89 (CH), 
126.403 (CH), 120.14 (C), 105.09 (CH2), 95.61 (CH), 78.09 (CH2), 50.93 (CH2), 45.43 
(CH2), 27.49 (CH3), 27.06 (CH2), 25.09 (CH2). 
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4-(5-cyano-indolin-1-yl)piperidine (18) 
An amount of 0.9 g (2.75 mmol) of tert-butyl 4-(5-cyano-indolin-1-yl)piperidine-1-
carboxylate (17) was dissolved in 11 mL of ethyl acetate-methanol mixture (1:1) and 
added of 3 mL of hydrochloric acid 32 % for 2 h. Once the reaction was completed 
(TLC monitoring)ba saturated solution of sodium bicarbonate was added in order to 
reach pH=8. After vacuum filtration and drying over overnight, the title compound was 
collected as a white powder. 
Yield: 80% 
M.W.:227.3; C14H17N3 
M.P.:143-145°C 
1H NMR (200 MHz, DMSO): δ 8.94 (br, NH), 7.39-7.35 (d, 1H, Ar), 7.27 (s, 1H, Ar), 
6.53-6.48 (d, 1H, Ar), 3.54-3.45 (m, 3H), 3.02-2.88 (m, 5H), 1.57-1.45 (m, 5H). 
 
73 
 
1-{1-[2-(p-chlorophenyl) acetyl] piperidin-4-yl}-indolin-5-carbonitrile (19a) 
0.227 g of 4-(5-cyano-indolin-1-yl)piperidine (18) (1.0 mmol) are dissolved in 1 mL of 
DMF and 4 mL of THF,.280 µL of triethylamine (2 mmol, d=0.726 g/mL) and 176 µL 
(1.2 mmol, d =1.292 g/mL) of p-chlorophenylacetyl chloride were. The reaction was 
stirred at room temperature overnight. The mixture was concentrated in vacuum and 
added of cold water. The crude mixture was washed with water (3x 10 mL) and 
extracted with dichloromethane. The organic layer was dried over magnesium sulfate 
and filtered. The solvent was removed under vacuum. The crude product was purified 
by flash chromatography (ethyl acetate). The combined fractions were evaporated 
leading to the pure product as a yellow powder. 
Yield: 40% 
M.W.: 379.86; C22H22ON3Cl 
M.P.: 163-165 °C 
1
H NMR (200 MHz CDCl3): δ 7.34-7.18 (m, 6H, Ar), 6.32-6.28 (d, 1H, Ar), 4.86-4.79 
(m, 1H), 4.01-3.94 (m, 1H), 3.73 (s, 2H), 3.65-3.37 (m, 3H), 3.14-2.89 (m, 3H), 2.69-
2.56 (m, 1H), 1.79-1.58 (m, 3H). 
13
C NMR (200 MHz CDCl3): δ 169.10 (C=O), 153.86(C), 133.6 (CH), 133.03 (C), 
130.68 (CH), 130.24 (CH2), 129.09 (CH2), 127.82 (CH), 121.01 (C-CN), 105.68 (CH2), 
98.65 (C), 52.89 (CH2), 46.85 (CH2), 45.81 (CH), 41.79 (CH), 28.49 (CH), 28.13 (CH), 
27.5 (CH). 
74 
 
2-(p-chlorophenyl)-1-{4-[5-(1H-tetrazol-5-yl)-1H-indolin -1-yl]piperidin-1-
yl}ethanone (20a) 
A screw cap vial was filled with nitrogen and charged with 0.15 g (0.39 mmol) of 1-{1-
[2-(p-chlorophenyl) acetyl] piperidin-4-yl}-indolin-5-carbonitrile (19), 104 µL of 
azido(trimethyl)silane (0.4 mmol, d=0.868 g/mL) and 200 µL (0.195 mmol) of 1M 
TBAF solution in THF. The vial was capped and heated at 120°C for 48 h. Afterwards 
the crude mixture (brown semisolid) was cooled at room temperature and washed with a 
2M solution of hydrochloric acid (3 X 5 mL) to give a yellow powder. The solid 
product was filtrated in vacuum and washed with water and purified by flash 
chromatography (ethyl acetate/acetonitrile; 10:1). The combined fractions were 
evaporated leading to the pure product as a yellow powder. 
Yield: 20% 
M.W.: 424.91; C22H23ON6Cl 
M.P.: 208-210 °C 
1H NMR (200 MHz, DMSO): δ 8.26 (s, 1H, Ar), 7.80-7.76 (m, 1H, Ar), 7.62-7.60 (d, 
1H, Ar), 7.41-7.26 (m, 4H, Ar), 6.65-6.63 (d, 1H), 4.74-4.57 (m, 1H), 4.16-4.00 (m, 1 
H), 3.80-3.75 (m, 2H, OC-CH2-Ar), 3.32-3.18 (m, 2H), 2.49-1.82 (m, 6H), 1.22-1.13 
(m, 3H). 
13C NMR (200 MHz, DMSO):  δ 211.14 (C), 167.86 (C=O), 134.36 (C), 131.30 (C), 
131.16 (C), 131.05 (C), 130.32 (CH2), 127.50 (CH2), 126.24 (C), 119.25 (CH), 114.50 
(C), 110.20 (CH), 101.62 (CH), 78.50 (C), 66.95 (CH), 52.88 (C), 52.10 (CH). 
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tert-Butyl 4-(5-bromo-1H-indol-1-yl)piperidine-1-carboxylate (21) 
tert-Butyl-4-(5-bromo-indolin-1-yl)piperidine-1-carboxylate (14) (0.381 g,1.0 mmol) 
was dissolved in 4 mL of THF. Afterwards, 3mL of a solution of 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) (0.27 g, 1.2 mmol) in THF was added dropwise and 
the solution was stirred at 0°C for 3 h. The reaction mixture was diluted with ethyl 
acetate (40mL) and was washed with sodium bicarbonate saturated solution (2x20mL) 
and brine (20mL). The organic layer was dried over magnesium sulfate and the solvent 
was evaporated in vacuum. The crude product was purified by flash chromatography 
(petroleum ether/ethyl acetate, 5:1). The combined fractions were evaporated leading to 
the pure product as a white powder. 
Yield: 90% 
M.W.: 379.31; C18H23O2N2Br 
M.P.: 91-93 °C 
1H NMR (200 MHz, DMSO): δ 7.72-7.71 (d, 1H, Ar), 7.58-7.54 (m, 2H, Ar, CH=C ), 
7.25-7.20 (dd, 1H, Ar), 6.44-6.43 (d, 1H, C=CH), 4.58-4.57 (m, 1H, N-CH), 4.14-4.07 
(m, 2H, CH2), 3.33-2.95 (m, 2H, CH2), 1.89-1.76 (m, 4H), 1.42 (s, 9H, Boc). 
13C NMR (200 MHz, DMSO): δ 153.11 (C=O), 133.34 (C), 129.12 (C), 126.00 (CH), 
122.65 (CH), 121.94 (CH), 111.12 (CH), 110.99 (C), 100.16 (CH), 78.24 (CH), 51.86 
(CH2), 31.34 (CH2), 27.55 (CH3). 
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4-(5-bromo-1H-indol-1-yl)piperidine (22) 
An amount of 0.38 g (1.0 mmol) of tert-Butyl 4-(5-bromo-1H-indol-1-yl)piperidine-1-
carboxylate (21) was solubilized in 5 mL of ethyl acetate and methanol mixture (1:3) 
and added of 0.5 mL of hydrochloric acid (32 %) and stirred at 30°C. After 3 h, the 
solution was concentrated in vacuum and a saturated solution of sodium bicarbonate 
was added until pH=8 leading to formation of a precipitate. After vacuum filtration and 
drying over vacuum overnight, the title compound was collected as a white powder. 
 
Yield: 80% 
M.W.: 279.05: C13H15N2Br 
M.P.:139-141 °C 
1H NMR (200 MHz, DMSO): δ 7.71 (s, 1H, Ar), 7.68-7.44 (m, 2H, Ar, CH=C), 7.24-
7.202(m, 1H, Ar), 6.45-6.45 (s, 1H, C=CH), 4.55-4.52 (m, 1H, N-CH), 3.198 (m, 2H), 
2.87-2.85 (m, 2H), 1.96-1.76 (m, 6H) 
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1-[4-(5-bromo-1H-indol-1-yl)piperidin-1-yl]-2-(p-chlorophenyl)ethanone (23a) 
4-(5-bromo-1H-indol-1-yl)piperidine (22) (0.09 g, 0.3 mmol) was dissolved in 5 ml of a 
DMF and THF mixture(3:2). The solution obtained, was added of 84 µL (0.6 mmol, 
d=0.726 g/mL) of triethylamine and 53 µL (0.39 mmol, d=1.292 g/mL) of p-
chlorophenylacetyl chloride. The mixture was stirred at room temperature overnight. 
The solution was concentrated in vacuum, and cold water was added. The crude product 
was extracted in chloroform dried over magnesium sulfate and the solvent was removed 
in vacuum. The crude product was purified by flash chromatography (,ethyl 
acetate/petroleum ether; 5:2). The combined fractions were evaporated leading to the 
pure product as a light yellow powder. 
Yield: 60% 
M.W.: 432.58; C21H20ON2ClBr 
M.P.:145-147°C 
1
H NMR (200 MHz, CDCl3): δ 7.74 (s, 1H, Ar), 7.35-7.06 (m, 6, Ar, CH=C), 6.46-6.45 
(d, 1H, C=CH), 4.92-4.86 (m, 1H), 4.42-4.31 (m, 1H, CH-N), 4.07-4.00 (m, 1H), 3.76 
(s, 2H), 3.26-3.13 (m, 2H), 2.82-2.69 (m, 2h), 2.16-1.89 (m, 2H,). 
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tert-Butyl 4-(5-cyano-1H-indol-1-yl)piperidine-1-carboxylate (24) 
Tert-butyl 4-(5-bromo-1H-indol-1-yl)piperidine-1-carboxylate (21) (0.57 g, 1.5 mmol), 
potassium ferrocyanide trihydrate (0.253 g, 0.6 mmol) and 
tetrakis(triphenylphosphyne)palladium(0) (0.05 g, 0.375 mmol) were charged in a vial 
which was capped, evacuated and filled with nitrogen. Then, 4.5 mL of a solution of 
water/tert-butanol (1:1) and 56 µL (0.375 mmol, d=1.018 g/mL) of DBU were added. 
The solution obtained was stirred at room temperature for 10 min and subsequently it 
was heated at 85°C in a pre-heated bath oil for 24 h. The reaction was filtered and  the 
cake was rinsed with 20 mL of methanol and 20 mL of dichloromethane. The solution 
obtained was dried over magnesium sulfate, filtrated and evaporated in vacuum. The 
crude mixture was adsorbed on silica gel and purified by flash chromatography (ethyl 
acetate/petroleum ether 1:4). The combined fractions were evaporated leading to the 
pure product as a white powder 
Yield: 80% 
M.W.: 326.33; C18H23O2N3 
M.P.: 121-123 °C 
1
H NMR (200 MHz, CDCl3): δ 7.98 (s, 1H, Ar), 7.43-7.42 (d, 2H), 7.31-7.29 (d, 1H), 
6.62-6.60 (d, 1H), 4.44-4.43 (m, 1H), 2.98-2.86 (m, 3H), 2.10-1.99 (m, 6H), 1.41 (s, 
9H). 
13
C NMR (200 MHz, DMSO-d6): 153.07 (C=O), 136.16 (CH), 127.25 (CH2), 127.02 
(CH2), 125.38 (CH2), 122.98 (CH2), 119.98 (C), 110.52 (CH), 101.69 (CH2), 100.58 
(CH), 78.24 (CH2), 51.86 (CH2), 31.26 (CH3). 
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4-(5-cyano-1H-indol-1-yl)piperidine (25) 
Tert-butyl 4-(5-cyano-1H-indol-1-yl)piperidine-1-carboxylate (24) (0.33 g, 1 mmol) 
was dissolved in 5 mL of a methanol/ethyl acetate solution (3:1) and then 1 mL of 
hydrochloric acid 32% was added. The solution was stirred at 30 °C for 3 h. Then the 
reaction was quenched with a saturated solution of sodium bicarbonate (15 mL) until 
pH=8 leading to a precipitate. After filtration and drying over overnight, the titled 
compound was collected as a white powder  
Yield: 90 % 
M.W.:225.03; C14H14N3 
M.P.: 148-150°C 
1
H NMR (200 MHz, DMSO-d6): δ 8.09 (s, 1H, Ar), 7.82-7.47 (m, 4H), 6.64 (s, 1H), 
4.71 (m 2H), 3.32-3.26 (m, 3H), 3.10-2.96 (m, 3H). 
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1-{1-[(p-chlorophenyl)acetyl]piperidin-4-yl}-1H-indole-5-carbonitrile (26a) 
0.225 g (1.0 mmol) of 4-(5-cyano-1H-indol-1-yl)piperidine (25) were dissolved in 1 mL 
of DMF and 7 mL of THF. The solution obtained was cooled at 0 °C and added of 600 
µL (4.3 mmol, d=0.726 g/mL) of triethylamine and 179 µL (1.2 mmol, d=1.292 g/mL) 
of p-chlorophenylacetyl chloride. The reaction was stirred at 0 °C for 1 h and kept to 
room temperature overnight. Then cold water was added and the crude product was 
extracted with chloroform which was dried over sulfate magnesium and filtered. The 
crude product was purified by flash chromatography (ethyl acetate). The combined 
fractions were evaporated leading to the pure product as a white powder. 
Yiled: 65% 
M.W.: 377.56; C22H20ON3Cl 
M.P.:174-172°C 
1
H NMR (200 MHz, CDCl3): δ 8.07-8.06 (d, 1H, Ar), 7.78-7.73 (d, 1H), 7.67-7.66 (d, 
1H, Ar), 7.49-7.23 (m, 7H), 6.61-6.60 (d, 1H, C=CH), 4.76-4.75 (m, 2H), 3.31 (s, 2H), 
3.31-3.22 (m, 3H), 1.96-1.89 (m, 2H). 
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2-(p-chlorophenyl)-1-{4-[5-(1H-tetrazol-5-yl)-1H-indole -1-yl]piperidin-1-
yl}ethanone (27a) 
A screw cap vial was charged with 0.094 g (0.25 mmol) of 1-{1-[(p-
chlorophenyl)acetyl]piperidin-4-yl}-1H-indole-5-carbonitrile (26a), 70 µL (0.5 mmol, 
d=0.868 g/ml) of azido(trimethyl)silane and 125 µL (0.125 mmol) of a 1M solution of 
TBAF in THF, under nitrogen. The mixture was stirred at 120 °C for 48 h. Then the 
crude mixture (brown semisolid) was cooled at room temperature and washed with a 
2M aqueous solution of hydrochloric acid (3 X 5 mL) leading a green precipitate. The 
solid was filtrated and washed with water and purified by flash chromatography (ethyl 
acetate). The combined fractions were evaporated leading to the pure product as a white 
powder. 
Yield: 16 % 
M.W.: 424.9; C22H21ON6Cl 
M.P.: 214-216°C 
1
H NMR (200 MHz, DMSO-d6): δ 8.24(s, 1H, Ar), 7.78 (m, 2H,), 7.35(s, 1H, Ar), 7.29-
7.25 (m, 4H), 6.619 (s, 1H, CH=C), 4.61 (m, 1H), 3.77-3.30 (m, 2H), 2.47 (m, 2H), 
1.92-1.48 (m, 6H). 
13
C NMR (200 MHz, DMSO-d6): δ 173.85 (C=O), 141.89 (C), 140.46 (CH2), 133.54 
(CH2), 132.24 (C), 125.25 (CH), 120.76 (C), 116.21 (CH), 107.63 (CH), 73.14 (CH2), 
73.13 (CH2), 58.09 (CH), 50.22 (CH), 37.82 (CH). 
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tert-Butyl 4-(5-bromo-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)piperidine-1-
carboxylate (28) 
An amount of 0.5 g (1.31 mmol) of tert-butyl 4-(5-bromo-1H-indol-1-yl)piperidine-1-
carboxylate (21) was solubilized in 6 mL of acetone, 13 mL of acetic acid and 4.5 mL 
of water. The solution was slowly added of (over 45 min) 1.7 g (13 mmol) of 
chromium(VI) oxide. The reaction mixture was stirred at room temperature for 2 h, and 
added of ice and extracted with dichloromethane. The organic phases were washed with 
water and saturated solution of sodium bicarbonate and dried over magnesium sulfate. 
The solvent was removed in vacuum and the residue was purified by flash 
chromatography (n-hexane/ethyl acetate; 3:1). The combined fractions were evaporated 
leading to the pure product as an orange powder. 
Yield: 28 % 
M.W.: 409.32; C18H19O2N2Br 
M.P.:165-167°C 
1
H NMR (200 Mhz, CDCl3): δ 7.41-7.34 (m, 2H, Ar), 7.04-6.99 (d, 1H, Ar), 4.19 (m, 
1H), 3.62-3.30 (m, 2H), 3.21-3.05 (m, 4H), 2.67-2.55 (m, 2H), 1.23 (s, 9H). 
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tert-Butyl 4-(5-cyano-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)piperidine-1-carboxylate 
(29) 
tert-Butyl 4-(5-bromo-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)piperidine-1-carboxylate 
(28) (0.17 g,  0.42 mmol), potassium ferrocyanide trihydrate (0.71 g, 0.17 mmol) and 
tetrakis(triphenylphosphyne)palladium(0) (0.02 g, 0.01 mmol) were charged in a vial, 
capped, evacuated and filled with nitrogen.  2 mL of a solution of water/tert-butanol 
(1:1) and 16 µL (0.1 mmol, d=1.018 g/mL) of DBU were added and stirred at room 
temperature for 10 min. Then the mixture was heated at 85°C in a pre-heated bath oil 
and stirred for 24 h. The reaction mixture was filtered and the cake was rinsed with 20 
mL of methanol and 20 mL of dichloromethane. The solution obtained was dried over 
magnesium sulfate, filtrated and solvents removed in vacuum. The crude product was 
brown oil hardly to purify. 
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